Journal of Clinical Psychiatry

Subject Index to Volume 63: January 2002 Through December 2002

Academic Highlights
Understanding changes in cholinergic function: implications for treating dementia. Mar 259–269
Adolescents
Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. Margolese. Nov 1040–1044
Is bipolar disorder specifically associated with panic disorder in youths? [CME] Birmaher. May 414–419
Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. Wernicke. Suppl 12, 50–55
Use of quetiapine in children and adolescents. Findling. Suppl 13, 27–31
Aggression
Anger and aggression in psychiatric outpatients. Posternak. Aug 665–672
Agitation
Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with *Melissa*. Ballard. July 553–558
Akathisia
Immediate effect of intravenous diazepam in neuroleptic-induced acute akathisia: an open-label study. Hirose. June 524–427
Algorithm
Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study [CME]. Adli. Sept 782–790
Alzheimer's Disease
Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: a pilot study. Sjögren. Nov 972–980
Amisulpride
Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. Maina. Jan 38–43
Anger
Anger and aggression in psychiatric outpatients. Posternak. Aug 665–672
Angiogenesis
Nicotine-induced angiogenesis [letter]. Schwartz; Shytle, Silver, Sanberg reply. Oct 949–950
Anticonvulsants see also specific drugs
Bipolar disorders and the effectiveness of novel anticonvulsants. Calabrese. Suppl 3, 5–9
Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. Yatham. Apr 275–283
Antidepressants see also specific drugs
Antidepressant medication management and health plan employer data information set (HEDIS) criteria: reasons for nonadherence. Kobak. Aug 727–732
Antidepressants and antipsychotics in the long-term treatment of bipolar disorder. Kusumakar. Suppl 10, 23–28
Beyond monoamine-based therapies: clues to new approaches. Skolnick. Suppl 2, 19–23
Can monoamine-based therapies be improved? Demitrack. Suppl 2, 14–18
Combined antidepressant treatment: a risk factor for switching in bipolar patients [letter]. Gabbay; Henry reply. Apr 367–368
Combining antidepressants for treatment-resistant depression: a review [CME]. Lam. Aug 685–693
Effects of antidepressant treatment on the quality of daily life: an experience sampling study [CME]. Barge-Schaapveld. June 477–485
Factors contributing to failed trials of new agents: can technology prevent some problems? Greist. Suppl 2, 8–13
Hepatotoxicity associated with the new antidepressants. García-Pando. Feb 135–137
Overview of psychiatric disorders and the role of newer antidepressants. Charney. Suppl 1, 3–9
Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. Hirschfeld. Sept 826–837
Pharmacology of antidepressants: focus on nefazodone. DeVane. Suppl 1, 10–17
Prevalence of sexual dysfunction among newer antidepressants. Clayton. Apr 357–366
Role of receptor binding profiles in antidepressant-induced sexual dysfunction [letter]. Haberfellner; Montejo reply. Feb 168
Selecting methodologies for the evaluation of differences in time to response between antidepressants [CME]. Montgomery. Aug 694–699
Studying new antidepressants: if there were a light at the end of the tunnel, could we see it? [commentary]. Thase. Suppl 2, 24–28
Unmet need: what justifies the search for a new antidepressant? Greden. Suppl 2, 3–7
Antipsychotics see also specific drugs
Antidepressants and antipsychotics in the long-term treatment of bipolar disorder. Kusumakar. Suppl 10, 23–28
Antipsychotic polypharmacy: squandering precious resources? [Brainstorms] Stahl. Feb 93–94
Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. Meltzer. Suppl 9, 25–29
Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia [CME]. Hofer. Jan 49–53
Cardiovascular and Metabolic Risks Associated With Schizophrenia and Antipsychotic Drug Treatment. Suppl 9, 1–32
Cardiovascular effects of antipsychotics used in bipolar illness. Piepho. Suppl 4, 20–23
Case of ziprasidone-induced mania and the role of 5-HT_{2A} in mood changes induced by atypical antipsychotics [letter]. Lu BY. Dec 1185–1186
Clinical management of cardiovascular risks during treatment with psychotropic drugs. Glassman. Suppl 9, 12–17
Comparison between the effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program [CME]. Meyer PS. Feb 108–116
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. Gianfrancesco. Oct 920–930
Differential prescription of maintenance antipsychotics to African American and white patients with new-onset bipolar disorder. Fleck. Aug 658–664
Effects of novel antipsychotics on glucose and lipid levels. Wirshing DA. Oct 856–865
Excessive antipsychotic dosing in 2 U.S. state hospitals. Diaz. Nov 998–1003
Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. Kornegay. Sept 758–762
Injection of depot antipsychotic medications in patients with schizophrenia [letter]. Fleishman; Bloch reply. Sept 840–842
Introduction: cardiovascular and metabolic risks associated with schizophrenia and antipsychotic drug treatment. Meltzer. Suppl 9, 3–4
Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs. Vieweg. Suppl 9, 18–24
Mechanisms of weight gain induced by antipsychotic drugs [letter]. Baptista. Mar 245–246
Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. Buse. Suppl 4, 37–41
Movement disorders associated with atypical antipsychotic drugs. Caroff. Suppl 4, 12–19
Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. Maguire. Suppl 4, 56–62
Reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. Ernst. Suppl 4, 42–55
Risk of cardiovascular disease and sudden death in schizophrenia. Davidson. Suppl 9, 5–11. Correction, Aug 744
Role of novel antipsychotics in bipolar disorders. Yatham. Suppl 3, 10–14

Sleep apnea associated with antipsychotic-induced obesity [letter]. Wirshing, Apr 369–370
What role do atypical antipsychotic drugs have in treatment-resistant depression? Thase, Feb 95–103
Anxiety see also specific disorders
Anxiety associated with comorbid depression. Möller, Suppl 14, 22–26
Anxiety: New Treatment Perspectives. Suppl 14, 1–36
Childhood and early-onset anxiety: treatment and biomarker studies. McCracken, Suppl 6, 8–11
Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder [BRAINSTORMS]. Stahl, Sept 756–757
Epidemiology of anxiety disorders: prevalence and societal costs. Lépine, Suppl 14, 4–8
Foreword: Global Research in Anxiety and Depression (GRAD) Network Consensus Conference. Keller, Suppl 8, 3
Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents [BRAINSTORMS]. Stahl, Oct 854–855
Introduction. Anxiety: new treatment perspectives. Rickels, Suppl 14, 3
Introduction: exploring the boundaries of obsessive-compulsive disorder and other anxiety disorders. Hollander, Suppl 6, 3–4
Overview of psychiatric disorders and the role of newer antidepressants. Charney, Suppl 1, 3–9
Predominance of anger in depressive disorders compared with anxiety disorders and somatoform disorders [CME]. Koh, June 486–492
Role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation. Klein E, Suppl 14, 27–33
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Ninan, May 434–441
Topiramate treatment for SSRI-induced weight gain in anxiety disorders. Van Ameringen, Nov 981–984
Aripiprazole
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Kane, Sept 763–771
Aromatherapy
Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with *Melissa*. Ballard, July 553–558
Atomoxetine
Drug development process for a product with a primary pediatric indication. Allen AJ, Suppl 12, 44–49
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. Spencer, Dec 1140–1147
Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. Wernicke, Suppl 12, 50–55
Attention-Deficit/Hyperactivity Disorder
Adaptive changes related to medication treatment of ADHD: listening to parents of children in clinical trials of a novel nonstimulant medication. Saylor, Suppl 12, 23–28
Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. Barkley, Suppl 12, 10–15
Management of ADHD in adults. Adler, Suppl 12, 29–35
Novel treatments for attention-deficit/hyperactivity disorder in children. Spencer, Suppl 12, 16–22
Novel Treatments for Attention-Deficit/Hyperactivity Disorder in Children and Adults. Suppl 12, 1–64
Overview and neurobiology of attention-deficit/hyperactivity disorder. Spencer, Suppl 12, 3–9
Psychosocial treatments for attention-deficit/hyperactivity disorder in children. Barkley, Suppl 12, 36–43
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. Spencer, Dec 1140–1147
Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. Wernicke, Suppl 12, 50–55
Autism
Normal P50 gating in children with autism [CME]. Kemner, Mar 214–217
Behavior Therapy
Behavior therapy attenuates clozapine-induced obsessions and compulsions [letter]. MacCabe, Dec 1179–1180
Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control. Greist, Feb 138–145
Benzodiazepines see also specific drugs
Role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation. Klein E, Suppl 14, 27–33
Binge-Eating Disorder
Open-label trial of sibutramine in obese patients with binge-eating disorder. Appolinario, Jan 28–30
Placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. Arnold, Nov 1028–1033
Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. Malhotra, Sept 802–806
Bipolar Disorders
Antidepressants and antipsychotics in the long-term treatment of bipolar disorder. Kusumakar, Suppl 10, 23–28
Association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study [CME]. Goldberg, Sept 791–795
Association of mild traumatic brain injury with bipolar disorder [letter]. Sagduyu, July 594
Bipolar disorders and the effectiveness of novel anticonvulsants. Calabrese, Suppl 3, 5–9
Carbamazepine and valproate in the maintenance treatment of bipolar disorder. Keck, Suppl 10, 13–17
Cardiovascular effects of antipsychotics used in bipolar illness. Piepho, Suppl 4, 20–23
Clinical features of bipolar depression [letter]. Benazzi; Mitchell PB reply, Jan 77–78
Combined antidepressant treatment: a risk factor for switching in bipolar patients [letter]. Gabbay; Henry reply, Apr 367–368
Comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. Zajecka, Dec 1148–1155
Correlates of overweight and obesity in 644 patients with bipolar disorder. McElroy, Mar 207–213
Demographic and clinical characteristics of individuals in a bipolar disorder case registry [CME]. Kupfer, Feb 120–125
Differential prescription of maintenance antipsychotics to African American and white patients with new-onset bipolar disorder. Fleck, Aug 658–664
Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. Frankenburg, May 442–446
Evidence-based long-term treatment of bipolar II disorder. Suppes, Suppl 10, 29–33
High frequency of residual depressive symptoms in bipolar II disorder: the need for a better treatment [letter]. Benazzi; Kupfer reply, Nov 1045–1046
Impact of reproductive events on the course of bipolar disorder in women [CME]. Freeman, Apr 284–287
Introduction: innovations in the management of bipolar disorders. Yatham, Suppl 3, 3–4
Introduction: long-term use of mood stabilizers in bipolar disorder. Bowden, Suppl 10, 3–4
Is bipolar disorder specifically associated with panic disorder in youths? [CME] Birmaher, May 414–419
Long-term treatment of bipolar disorder with lamotrigine. Calabrese, Suppl 10, 18–22
Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. O'Donovan, Apr 322–330
Obsessive-compulsive–bipolar comorbidity: a systematic exploration of clinical features and treatment outcome [CME]. Perugi, Dec 1129–1134
Predictors of treatment response in bipolar disorders: evidence from clinical and brain imaging studies. Ketter, Suppl 3, 21–25
Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. Fagiolini, June 528–533
Prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. Duffy, Dec 1171–1178
Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. McIntyre, Suppl 3, 15–20
Randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. Vieta, June 508–512
Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. Goodwin, Suppl 10, 5–12
Report of the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder 2000. Suppes, Apr 288–299
Risk factors for completed suicide in bipolar disorder. Tsai, June 469–476

Role of novel antipsychotics in bipolar disorders. Yatham, Suppl 3, 10–14
Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. Ketter, Feb 146–151
Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. Altshuler, Sept 807–811
Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. Yatham, Apr 275–283

Books Reviewed

Allen J: *Traumatic Relationships and Serious Mental Disorders.* Racy, Sept 846
American Psychiatric Association Council on Aging Committee on Long-Term Care and Treatment of the Elderly. Greene JA, Loebel P (eds): *Manual of Nursing Home Practice for Psychiatrists.* Kwentus, Aug 747–748
American Psychiatric Association: *Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd ed.* Passmore, Apr 371
American Psychiatric Association Task Force: *Handbook of Psychiatric Measures.* Feeny and Ronis, Mar 253
American Psychiatric Press: *American Psychiatric Press Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2000.* Morris, Jan 81–82
Ayd FJ Jr: *Lexicon of Psychiatry, Neurology and the Neurosciences, 2nd ed.* Rao, Feb 171
Bezchlibnyk-Butler KZ, Jeffries JJ (eds): *Clinical Handbook of Psychotropic Drugs, 11th ed., revised.* Dunner, Mar 254
Bogousslavsky J, Cummings JL (eds): *Behavior and Mood Disorders in Focal Brain Lesions.* Farmer, Jan 81
Committee on Human Sexuality for the Group for the Advancement of Psychiatry: *Homosexuality and the Mental Health Professions: The Impact of Bias.* Elam, Jan 80–81
Conn DK, Herrmann N, Kaye A, Rewilak D, Schogt B: *Practical Psychiatry in the Long-Term Care Facility: A Handbook for Staff, 2nd Revised and Expanded ed.* Brown, June 541–542
Daley DC, Salloum IM (eds): *Clinician's Guide to Mental Illness.* Finlayson, Nov 1051–1052
Dewan NA, Lorenzi NM, Riley RT, Bhattacharya SR (eds): *Behavioral Healthcare Informatics (Health Informatics Series).* Kramer, Aug 745
Dilts SL Jr: *Models of the Mind: A Framework for Biopsychosocial Psychiatry.* Salomon, Jan 80
Došen A, Day K (eds): *Treating Mental Illness and Behavior Disorders in Children and Adults With Mental Retardation.* Thompson, Mar 252–253
Dougherty DD, Rauch SL (eds): *Psychiatric Neuroimaging Research: Contemporary Strategies.* Black, Nov 1052
Eth S (ed): *PTSD in Children and Adolescents.* Lamps, June 541
Ethics Committee of the American Psychiatric Association: *Opinions of the Ethics Committee on the Principles of Medical Ethics With Annotations Especially Applicable to Psychiatry: 2001 Edition.* Finder, Nov 1053
Ethics Committee of the American Psychiatric Association: *The Principles of Medical Ethics With Annotations Especially Applicable to Psychiatry: 2001 Edition.* Finder, Nov 1053
Gerrity E, Keane TM, Tuma F (eds): *The Mental Health Consequences of Torture (Plenum Series on Stress and Coping).* Wahid, Aug 747
Goldstein WN: *A Primer for Beginning Psychotherapy, 2nd ed.* Perlmutter, Apr 374
Graessner S, Gurris N, Pross C (eds): *At the Side of Torture Survivors: Treating a Terrible Assault on Human Dignity.* Lomax, May 458
Green MF: *Schizophrenia Revealed: From Neurons to Social Interactions.* Marder, June 542
Greenhill LL (ed): *Learning Disabilities: Implications for Psychiatric Treatment.* Sarles, June 540–541
Gunderson JG: *Borderline Personality Disorder: A Clinical Guide.* Schwab, Dec 1187
Gunderson JG, Gabbard GO (eds): *Psychotherapy for Personality Disorders (Review of Psychiatry series, vol. 19).* Silverman, May 457
Hobson JA: *The Dream Drugstore: Chemically Altered States of Consciousness.* Gillin, June 540
Heinrichs RW: *In Search of Madness: Schizophrenia and Neuroscience.* Nasrallah, Sept 845
Hornstein GA: *To Redeem One Person Is to Redeem the World: The Life of Frieda Fromm-Reichmann.* Gabbard, June 539–540
Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr: *Principles and Practice of Psychopharmacotherapy, 3rd ed.* Folks, Aug 748
Jenkins SC, Tinsley JA, Van Loon JA: *A Pocket Reference for Psychiatrists, 3rd ed.* Ciraulo, Sept. 844–845
Keltner NL, Folks DG: *Psychotropic Drugs, 3rd ed.* Daniel, Apr 372
Lichter DG, Cummings JL (eds): *Frontal-Subcortical Circuits in Psychiatric and Neurological Disorders.* Palmer, Oct 952
Maris RW, Berman AL, Silverman MM: *Comprehensive Textbook of Suicidology.* Joseph, Aug 745–746
McEvoy JP: *Guide to Assessment Scales in Schizophrenia.* Lee, May 458
Mesulam M-M (ed): *Principles of Behavioral and Cognitive Neurology, 2nd ed.* Kirshner, Jan 82
Nutt D, Davidson JRT, Zohar J (eds): *Posttraumatic Stress Disorder: Diagnosis, Management, and Treatment.* Farmer, Aug 746
Remschmidt H (ed): *Schizophrenia in Children and Adolescents.* Meltzer, Mar 252
Rickel AU, Wise TN: *Understanding Managed Care: An Introduction for Health Care Professionals.* Fishel-Ingram, Apr 373
Rogers R, Shuman DW: *Conducting Insanity Evaluations, 2nd ed.* Diner, Feb 170–171
Ruiz P (ed): *Ethnicity and Psychopharmacology (Review of Psychiatry series, vol. 19).* Hillard, May 459
Sadock BJ, Sadock VA (eds): *Kaplan & Sadock's Pocket Handbook of Clinical Psychiatry, 3rd ed.* Strain, Oct 952–953
Salloway SP, Malloy PF, Duffy JD (eds): *The Frontal Lobes and Neuropsychiatric Illness.* Benjamin, July 598
Schatzberg AF, Nemeroff CB (eds): *Essentials of Clinical Psychopharmacology.* Garver, June 539
Schetky DH, Benedek EP (eds): *Principles and Practice of Child and Adolescent Forensic Psychiatry.* Bernet, Oct 951
Schuckit MA: *Drug and Alcohol Abuse: A Clinical Guide to Diagnosis and Treatment, 5th ed.* Weinstein, May 459
Shafii M (ed): *School Violence: Assessment, Management, Prevention.* Harmon, Sept 843–844
Simon RI: *Concise Guide to Psychiatry and Law for Clinicians, 3rd ed.* Metzner, Nov 1052–1053
Slavney PR, Hurko O (eds): *The Primary Care Physician's Guide to Common Psychiatric and Neurologic Problems: Advice on Evaluation and Treatment From Johns Hopkins.* Wynn, Aug 746–747
Spar JE, La Rue A: *Concise Guide to Geriatric Psychiatry, 3rd ed.* Flacker, Sept 845
Steiner M, Yonkers KA, Eriksson E (eds): *Mood Disorders in Women.* Bernstein, Apr 373
Stotland NL, Stewart DE (eds): *Psychological Aspects of Women's Health Care: The Interface Between Psychiatry and Obstetrics and Gynecology, 2nd ed.* Goldstein MZ, May 456–457
Stoudemire A, Fogel BS, Greenberg DB (eds): *Psychiatric Care of the Medical Patient, 2nd ed.* Regan, Apr 371–372
Tseng W-S: *Handbook of Cultural Psychiatry.* Vaillant, July 598–599
Tseng W-S, Streltzer J (eds): *Culture and Psychotherapy: A Guide to Clinical Practice.* Ford, Nov 1051
Vance HB, Pumariega AJ (eds): *Clinical Assessment of Child and Adolescent Behavior.* Petti, May 457
Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP: *Combining Medication and Psychosocial Treatments for Addictions: The BRENDA Approach.* Hodo, Oct 951–952
Wadden TA, Stunkard J (eds): *Handbook of Obesity Treatment.* Mitchell, Dec 1187–1188
Warner R: *The Environment of Schizophrenia: Innovations in Practice, Policy and Communications.* Kopelowicz, Apr 374
Wedding D (ed): *Behavior and Medicine, 3rd ed.* Nash, Sept 843
White CA: *Cognitive Behaviour Therapy for Chronic Medical Problems: A Guide to Assessment and Treatment in Practice.* Slaughter, Apr 372–373
Yilmaz AT, Weiss MG, Riecher-Rössler A (eds): *Cultural Psychiatry: Euro-International Perspectives.* Ruiz, Feb 170

Borderline Personality Disorder

Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. Frankenburg, May 442–446
Treatment of borderline personality disorder with risperidone. Rocca, Mar 241–244

Brain Imaging see also specific technique

Predictors of treatment response in bipolar disorders: evidence from clinical and brain imaging studies. Ketter, Suppl 3, 21–25

Brain Injury

Association of mild traumatic brain injury with bipolar disorder [letter]. Sagduyu, July 594

Brainstorms

Antipsychotic polypharmacy: squandering precious resources? Stahl, Feb 93–94

Awakening to the psychopharmacology of sleep and arousal: novel neurotransmitters and wake-promoting drugs. Stahl, June 467–468
Can psychopharmacologic treatments that relieve symptoms also prevent disease progression? Stahl, Nov 961–962
Does depression hurt? Stahl, Apr 273–274
Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. Stahl, Sept 756–757
Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents. Stahl, Oct 854–855
Metabolic syndrome: psychopharmacologists should weigh the evidence for weighing the patient. Stahl, Dec 1094–1095
Mirror, mirror on the wall, which enantiomer is fairest of them all? Stahl, Aug 656–657
Psychopharmacology of energy and fatigue. Stahl, Jan 7–8
Psychopharmacology of painful physical symptoms in depression. Stahl, May 382–383
Psychopharmacology of wakefulness: pathways and neurotransmitters. Stahl, July 551–552
Selective actions on sleep or anxiety by exploiting GABA-A/benzodiazepine receptor subtypes. Stahl, Mar 179–180
Bright-Light Therapy see Phototherapy
Bupropion
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. Kennedy, Mar 181–186
Serum bupropion levels in 2 breastfeeding mother-infant pairs. Baab, Oct 910–911
Burning Mouth Syndrome
Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. Maina, Jan 38–43
Carbamazepine
Carbamazepine and valproate in the maintenance treatment of bipolar disorder. Keck, Suppl 10, 13–17
Carbamazepine augmentation for schizophrenia: how good is the evidence? Leucht, Mar 218–224
Cardiovascular System
Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. Meltzer, Suppl 9, 25–29
Cardiovascular effects of antipsychotics used in bipolar illness. Piepho, Suppl 4, 20–23
Clinical management of cardiovascular risks during treatment with psychotropic drugs. Glassman, Suppl 9, 12–17
Introduction: cardiovascular and metabolic risks associated with schizophrenia and antipsychotic drug treatment. Meltzer, Suppl 9, 3–4
Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs. Vieweg, Suppl 9, 18–24
Risk of cardiovascular disease and sudden death in schizophrenia. Davidson, Suppl 9, 5–11. Correction, Aug 744
Charcoal
Burning charcoal: an indigenous method of committing suicide in Hong Kong. Leung, May 447–450
Children
Adaptive changes related to medication treatment of ADHD: listening to parents of children in clinical trials of a novel nonstimulant medication. Saylor, Suppl 12, 23–28
Childhood and early-onset anxiety: treatment and biomarker studies. McCracken, Suppl 6, 8–11
Drug development process for a product with a primary pediatric indication. Allen AJ, Suppl 12, 44–49
Is bipolar disorder specifically associated with panic disorder in youths? [CME] Birmaher, May 414–419
Novel treatments for attention-deficit/hyperactivity disorder in children. Spencer, Suppl 12, 16–22
Psychosocial treatments for attention-deficit/hyperactivity disorder in children. Barkley, Suppl 12, 36–43
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. Spencer, Dec 1140–1147
Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. Wernicke, Suppl 12, 50–55
Use of quetiapine in children and adolescents. Findling, Suppl 13, 27–31
What research suggests for depressed women with children [CME]. Weissman, July 641–647
Cholinergic Therapy
Understanding changes in cholinergic function: implications for treating dementia [ACADEMIC HIGHLIGHTS]. Mar 259–269
Citalopram
Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. Pallanti, Sept 796–801
Citalopram treatment of compulsive shopping: an open-label study. Koran, Aug 704–708
Exacerbation of idiopathic priapism with risperidone-citalopram combination [letter]. Freudenreich, Mar 249–250
Interferon-induced depression treated with citalopram [letter]. Farah, Feb 166–167
Open-label study of citalopram in the treatment of pathological gambling. Zimmerman, Jan 44–48
Open-label trial of citalopram for major depression in patients with hepatitis C. Gleason, Mar 194–198
Organic hypomania secondary to sibutramine-citalopram interaction [letter]. Benazzi, Feb 165
Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. Miner, Mar 232–240
Clomipramine
Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. Albert, Nov 1004–1009
Clozapine
Behavior therapy attenuates clozapine-induced obsessions and compulsions [letter]. MacCabe, Dec 1179
Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. Umbricht, May 420–424
Clozapine and tardive dyskinesia [letter]. Kumet, Feb 167–168
Clozapine-induced fevers and 1-year clozapine discontinuation rate. Tham, Oct 880–884
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. Gianfrancesco, Oct 920–930
Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. Borovicka, Apr 345–348
Cocaine
Olanzapine for cocaine craving and relapse prevention in 2 patients [letter]. Longo, July 595–596
Olanzapine treatment for patients with schizophrenia and cocaine abuse [letter]. Tsuang, Dec 1180–1181
Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Differential effects of nefazodone and Cognitive Behavioral Analysis System of Psychotherapy on insomnia associated with chronic forms of major depression. Thase, June 493–500
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, Cognitive Behavioral Analysis System of Psychotherapy, and their combination. Ninan, May 434–441
Cognitive-Behavioral Therapy
Randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. Kampman, Sept 772–777
Comorbidity
Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study. Melartin, Feb 126–134
Major depressive disorder and axis I diagnostic comorbidity [CME]. Zimmerman, Mar 187–193
Compulsive Shopping
Citalopram treatment of compulsive shopping: an open-label study. Koran, Aug 704–708
Corrections see also Retraction
Risk of cardiovascular disease and sudden death in schizophrenia. Davidson, Suppl 9, 5–11. Correction, Aug 744
Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. Vieta, 2001 Oct 818–825. Correction, Jan 79
Costs of Medical Care
Cost savings with nefazodone in treating depression. Hales, Suppl 1, 48–51
Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans. Polsky, Feb 156–164
Epidemiology of anxiety disorders: prevalence and societal costs. Lépine, Suppl 14, 4–8
Impact of treatment-resistant depression on health care utilization and costs [CME]. Crown, Nov 963–971
Identification of a claims data "signature" and economic consequences for treatment-resistant depression. Corey-Lisle, Aug 717–726
Cross-Cultural Psychiatry
Association between high nicotine dependence and

severe mental illness may be consistent across countries. de Leon, Sept 812–816
Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. Ohayon, Sept 817–825

Delirium

Delirium caused by donepezil: a case study [letter]. Kawashima, Mar 250–251

Delusions

Delusions associated with quetiapine-related weight redistribution [letter]. Wirshing DA, Mar 247–248
Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis [letter]. Fawcett, Feb 169

Dementia see also Alzheimer's Disease

Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with *Melissa*. Ballard, July 553–558
Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. Fernandez, June 513–515
Understanding changes in cholinergic function: implications for treating dementia [ACADEMIC HIGHLIGHTS]. Mar 259–269

Depression

Alternative treatments for depression: empirical support and relevance to women [CME]. Manber, July 628–640
Anxiety associated with comorbid depression. Möller, Suppl 14, 22–26
Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK_1). Santarelli, Suppl 11, 11–17
Chronic depression in women [CME]. Kornstein, July 602–609
Clinical experience with substance P receptor (NK_1) antagonists in depression. Krishnan, Suppl 11, 25–29
Clinical use of nefazodone in major depression: a 6-year perspective. Schatzberg, Suppl 1, 18–31
Combining antidepressants for treatment-resistant depression: a review [CME]. Lam, Aug 685–693
Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect. Overbeek, Dec 1106–1112
Cost savings with nefazodone in treating depression. Hales, Suppl 1, 48–51
Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study. Melartin, Feb 126–134
Depression during pregnancy: diagnosis and treatment options. Nonacs, Suppl 7, 24–30
Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. Thase, June 493–500
Does depression hurt? [BRAINSTORMS] Stahl, Apr 273–274
Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. Goldstein DJ, Mar 225–231
Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. Detke, Apr 308–315
Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study [CME]. Adli, Sept 782–790
Effect of reboxetine on depression in Parkinson's disease patients. Lemke, Apr 300–304
Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. Golden RN, July 577–584
Efficacy of continuation treatment with *Hypericum perforatum* in depression [letter]. Brenner, May 455
Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. Sajatovic, Dec 1156–1163
Efficacy of 17β-estradiol on depression: is estrogen deficiency really necessary? [letter] Soares; Ahokas reply, May 451–452
Epidemiology of depression throughout the female life cycle. Burt, Suppl 7, 9–15
Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. Rasgon, Suppl 7, 45–48
Exploring the relationship between depression and erectile dysfunction in aging men. Seidman, Suppl 5, 5–12
Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. Burke, Apr 331–336
Foreword: Global Research in Anxiety and Depression (GRAD) Network Consensus Conference. Keller, Suppl 8, 3
Generalized anxiety and depression in primary care: prevalence, recognition, and management. Wittchen, Suppl 8, 24–34
Identification of a claims data "signature" and economic consequences for treatment-resistant depression. Corey-Lisle, Aug 717–726
Imaging substance P receptors (NK_1) in the living human brain using positron emission tomography. Hargreaves, Suppl 11, 18–24
Impact of treatment-resistant depression on health care utilization and costs [CME]. Crown, Nov 963–971
Interferon-induced depression treated with citalopram [letter]. Farah, Feb 166–167
Introduction. Pathophysiology of depression: the emerging role of substance P. Krishnan, Suppl 11, 4–5
Introduction: women and depression. Mazure, July 600–609
Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. Normann, Apr 337–344
Lamotrigine as an augmentation agent in treatment-resistant depression. Barbee, Aug 737–741
Longitudinal view of triggers and thresholds of suicidal behavior in depression [CME]. Pezawas, Oct 866–873
Major depressive disorder and axis I diagnostic comorbidity [CME]. Zimmerman, Mar 187–193
Neurobiology of substance P and the NK_1 Receptor. Mantyh, Suppl 11, 6–10
Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study. Marangell, May 391–395
Open-label trial of citalopram for major depression in patients with hepatitis C. Gleason, Mar 194–198
Open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. Matthews, Dec 1164–1170
Overview of psychiatric disorders and the role of newer antidepressants. Charney, Suppl 1, 3–9
Overview: the use of SSRIs in depressive disorders specific to women. Altshuler, Suppl 7, 3–8
Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. Cassano, May 396–402
Pathophysiology of Depression: The Emerging Role of substance P. Suppl 11, 1–32
Pharmacologic treatment of depression: is gender a critical factor? [CME] Yonkers, July 610–615
Predominance of anger in depressive disorders compared with anxiety disorders and somatoform disorders [CME]. Koh, June 486–492
Psychopharmacology of painful physical symptoms in depression [BRAINSTORMS]. Stahl, May 382–383
Randomized comparison of high-charge right unilateral electroconvulsive therapy and bilateral electroconvulsive therapy in older depressed patients who failed to respond to 5 to 8 moderate-charge right unilateral treatments. Tew, Dec 1102–1105
Randomized trial of the efficacy of bright-light exposure and aerobic exercise on depressive symptoms and serum lipids [CME]. Leppämäki, Apr 316–321
Risk factors for falls during treatment of late-life depression. Joo, Oct 936–941
Sex differences in depressed substance abusers [CME]. Sinha, July 616–627
Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. Zajecka, Aug 709–716
Six-year perspectives on the safety and tolerability of nefazodone. Dunner, Suppl 1, 32–41
Somatic symptoms, depression, and antidepressant treatment [commentary]. Fava, Apr 305–307
Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. Altshuler, Sept 807–811
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Ninan, May 434–441
Testosterone therapy in late-life major depression in males. Perry, Dec 1096–1101
Treatment of postpartum depression: minimizing infant exposures. Newport, Suppl 7, 31–44
What research suggests for depressed women with children [CME]. Weissman, July 641–647
What role do atypical antipsychotic drugs have in treatment-resistant depression? Thase, Feb 95–103

Diabetes

Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. Gianfrancesco, Oct 920–930
Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. Kornegay, Sept 758–762
Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. Buse, Suppl 4, 37–41

Risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. Caro, Dec 1135–1139

Diazepam

Immediate effect of intravenous diazepam in neuroleptic-induced acute akathisia: an open-label study. Hirose, June 524–427

Divalproex Sodium

Comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. Zajecka, Dec 1148–1155

Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. Frankenburg, May 442–446

Donepezil

Delirium caused by donepezil: a case study [letter]. Kawashima, Mar 250–251

Dosage

Excessive antipsychotic dosing in 2 U.S. state hospitals. Diaz, Nov 998–1003

Drug Development

Drug development process for a product with a primary pediatric indication. Allen AJ, Suppl 12, 44–49

Duloxetine

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. Goldstein DJ, Mar 225–231

Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. Detke, Apr 308–315

Dystonia

Dystonia induced by mirtazapine [letter]. Lu R, May 452–453

Eating Disorders

Sleep-related eating disorder induced by olanzapine [letter]. Paquet, July 597

Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. Malhotra, Sept 802–806

Elderly

Abstracts of the 2002 Annual Meeting of The International College of Geriatric Psychoneuropharmacology. Nov 1054–1086

No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. Barak, Feb 117–119

Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. Cassano, May 396–402

Use of quetiapine in elderly patients. Tariot, Suppl 13, 21–26

Electroconvulsive Therapy

Randomized comparison of high-charge right unilateral electroconvulsive therapy and bilateral electroconvulsive therapy in older depressed patients who failed to respond to 5 to 8 moderate-charge right unilateral treatments. Tew, Dec 1102–1105

Eosinophilia

Eosinophilia associated with olanzapine [letter]. Mathias, Mar 246–247

Escitalopram

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. Burke, Apr 331–336

Estrogen

Efficacy of 17β-estradiol on depression: is estrogen deficiency really necessary? [letter] Soares; Ahokas reply, May 451–452

Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. Rasgon, Suppl 7, 45–48

Ethnicity

Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. Emsley, Jan 9–14

Exercise

Randomized trial of the efficacy of bright-light exposure and aerobic exercise on depressive symptoms and serum lipids [CME]. Leppämäki, Apr 316–321

Eye Movement Desensitization and Reprocessing (EMDR)

EMDR for women who experience traumatic events [letter]. Peterson; Foa reply, Nov 1047–1048

Fatigue

Psychopharmacology of energy and fatigue [BRAINSTORMS]. Stahl, Jan 7–8

Fluoxetine

Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. Kennedy, Mar 181–186

Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans. Polsky, Feb 156–164

Fluoxetine-induced sexual dysfunction reversed by loratadine [letter]. Brubaker, June 534

Fluoxetine versus placebo in posttraumatic stress disorder. Martenyi, Mar 199–206

Open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. Matthews, Dec 1164–1170

Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. Cassano, May 396–402

Placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. Arnold, Nov 1028–1033

Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. Miner, Mar 232–240

Fluvoxamine

Fluvoxamine treatment of a Japanese patient with koro [letter]. Nakaya, Dec 1182–1183

Randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Turkington, Sept 778–781

France

Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. Ohayon, Sept 817–825

Gabapentin

Gabapentin and PTSD [letter]. Berigan, Aug 744

Gender

Pharmacologic treatment of depression: is gender a critical factor? [CME] Yonkers, July 610–615

Sex differences in depressed substance abusers [CME]. Sinha, July 616–627

Generalized Anxiety Disorder

Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. Llorca, Nov 1020–1027

Generalized anxiety and depression in primary care: prevalence, recognition, and management. Wittchen, Suppl 8, 24–34

Generalized anxiety disorder in primary care: emerging issues in management and treatment. Culpepper, Suppl 8, 35–42

Long-term clinical course of generalized anxiety disorder. Keller, Suppl 8, 11–16

Patterns and correlates of generalized anxiety disorder in community samples. Kessler, Suppl 8, 4–10

Pharmacotherapy of generalized anxiety disorder. Rickels, Suppl 14, 9–16

Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. Stein, Suppl 6, 12–19

Surprising results in the study of paroxetine for generalized anxiety disorder [letter]. Ballas; Pollack reply, June 536–537

Treatment of generalized anxiety disorder. Gorman, Suppl 8, 17–23

Genetics

Prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. Duffy, Dec 1171–1178

Recent findings in the genetics of OCD. Pato, Suppl 6, 30–33

Geriatric Psychiatry see Elderly

Germany

Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. Ohayon, Sept 817–825

Haloperidol

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Kane, Sept 763–771

28-Week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. Hirsch, June 516–523

Hepatitis

Open-label trial of citalopram for major depression in patients with hepatitis C. Gleason, Mar 194–198

Hepatotoxicity

Hepatotoxicity associated with the new antidepressants. García-Pando, Feb 135–137

Hoarding

Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment [CME]. Saxena, Jan 21–27

Hydroxyzine

Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. Llorca, Nov 1020–1027

Hyperglycemia

Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. Buse, Suppl 4, 37–41

Resolution of hyperglycemia on risperidone discontinuation: a case report [letter]. Mallya, May 453–454

Hypericum perforatum

Efficacy of continuation treatment with *Hypericum perforatum* in depression [letter]. Brenner, May 455

Hyperinsulinemia

Hyperinsulinemia in psychiatric patients treated with olanzapine [letter]. Cohn, Jan 75–76

Hypertriglyceridemia
Severe hypertriglyceridemia associated with olanzapine [letter]. Stoner, Oct 948–949
Hypokalemia
Hypokalemia with venlafaxine [letter]. Shang, Nov 1049–1050
Hypomania
Organic hypomania secondary to sibutramine-citalopram interaction [letter]. Benazzi, Feb 165
Infants
Serum bupropion levels in 2 breastfeeding mother-infant pairs. Baab, Oct 910–911
Treatment of postpartum depression: minimizing infant exposures. Newport, Suppl 7, 31–44
Insomnia
Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. Thase, June 493–500
Interferon
Interferon-induced depression treated with citalopram [letter]. Farah, Feb 166–167
Italy
Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. Ohayon, Sept 817–825
Journal of Clinical Psychiatry
Brainstorms—5 years and counting. July 550
Gratitude [editorial]. Gelenberg, Jan 4–6
Kleptomania
Open-label study of naltrexone in the treatment of kleptomania. Grant, Apr 349–356
Koro
Fluvoxamine treatment of a Japanese patient with koro [letter]. Nakaya, Dec 1182–1183
Lamotrigine
Lamotrigine and rash: scratching beneath the surface [commentary]. Labiner, Nov 1010–1011
Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. Normann, Apr 337–344
Lamotrigine as an augmentation agent in treatment-resistant depression. Barbee, Aug 737–741
Long-term treatment of bipolar disorder with lamotrigine. Calabrese, Suppl 10, 18–22
Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. Calabrese, Nov 1012–1019
Light Therapy see Phototherapy
Lithium
Is response to prophylactic lithium a familial trait? Grof, Oct 942–947
Lithium and valproate treatment of pathological gambling: a randomized single-blind study. Pallanti, July 559–564
Prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. Duffy, Dec 1171–1178
Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. Goodwin, Suppl 10, 5–12
Loratadine
Fluoxetine-induced sexual dysfunction reversed by loratadine [letter]. Brubaker, June 534
Mania
Switch to mania after slow rTMS of the right prefrontal cortex [letter]. Ella, Mar 249
Melissa officinalis
Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with *Melissa*. Ballard, July 553–558
Men
Exploring the relationship between depression and erectile dysfunction in aging men. Seidman, Suppl 5, 5–12
Testosterone therapy in late-life major depression in males. Perry, Dec 1096–1101
Mental Illness
Association between high nicotine dependence and severe mental illness may be consistent across countries. de Leon, Sept 812–816
Metabolism
Effects of novel antipsychotics on glucose and lipid levels. Wirshing DA, Oct 856–865
Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. Buse, Suppl 4, 37–41
Retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. Meyer JM, May 425–433
Micronutrients
Role of micronutrients as possible mood-stabilizing agents [letter]. Pies; Kaplan reply, Aug 742–744
Mirtazapine
Dystonia induced by mirtazapine [letter]. Lu R, May 452–453
Restless legs syndrome induced by mirtazapine [letter]. Ağargün, Dec 1179
Urinary incontinence with mirtazapine [letter]. Kunwar, May 454
Venlafaxine in a patient with idiopathic leukopenia and mirtazapine-induced severe neutropenia [letter]. Anghelescu, Sept 838
Mood Stabilizers
Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. Keck, Suppl 4, 3–11
Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder [CME]. Goldberg, Nov 985–991
Nonadherence with mood stabilizers: prevalence and predictors [CME]. Scott, May 384–390
Reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. Ernst, Suppl 4, 42–55
Role of micronutrients as possible mood-stabilizing agents [letter]. Pies; Kaplan reply, Aug 742–744
Movement Disorders
Movement disorders associated with atypical antipsychotic drugs. Caroff, Suppl 4, 12–19
Naltrexone
Open-label study of naltrexone in the treatment of kleptomania. Grant, Apr 349–356
Nefazodone
Antidepressant dosing and switching guidelines: focus on nefazodone. Zajecka, Suppl 1, 42–47
Clinical use of nefazodone in major depression: a 6-year perspective. Schatzberg, Suppl 1, 18–31
Cost savings with nefazodone in treating depression. Hales, Suppl 1, 48–51
Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. Thase, June 493–500
Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. Pallanti, Nov 1034–1039
Overview of psychiatric disorders and the role of newer antidepressants. Charney, Suppl 1, 3–9
Pharmacology of antidepressants: focus on nefazodone. DeVane, Suppl 1, 10–17
Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. Zajecka, Aug 709–716
Six-year perspectives on the safety and tolerability of nefazodone. Dunner, Suppl 1, 32–41
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Ninan, May 434–441
Neutropenia
Venlafaxine in a patient with idiopathic leukopenia and mirtazapine-induced severe neutropenia [letter]. Anghelescu, Sept 838
Nicotine
Association between high nicotine dependence and severe mental illness may be consistent across countries. de Leon, Sept 812–816
Nicotine-induced angiogenesis [letter]. Schwartz; Shytle, Silver, Sanberg reply, Oct 949–950
Nomenclature
Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. Ketter, Feb 146–151
Noncompliance
Antidepressant medication management and health plan employer data information set (HEDIS) criteria: reasons for nonadherence. Kobak, Aug 727–732
Predictors of noncompliance in patients with schizophrenia [CME]. Perkins, Dec 1121–1128
Obesity see Weight
Obsessive-Compulsive Disorder
Behavior therapy attenuates clozapine-induced obsessions and compulsions [letter]. MacCabe, Dec 1179–1180
Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control. Greist, Feb 138–145
Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. Pallanti, Sept 796–801
Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect. Overbeek, Dec 1106–1112
Exploring the Boundaries of Obsessive-Compulsive Disorder and Other Anxiety Disorders: New Developments and Practical Approaches From the Fifth International OCD Conference. Suppl 6, 1–36
Introduction: exploring the boundaries of obsessive-compulsive disorder and other anxiety disorders. Hollander, Suppl 6, 3–4
Obsessive-compulsive–bipolar comorbidity: a systematic exploration of clinical features and treatment outcome [CME]. Perugi, Dec 1129–1134
Obsessive-compulsive disorder: defining the phenotype. Nestadt, Suppl 6, 5–7
Obsessive-compulsive disorder with non–24-hour sleep-wake syndrome [letter]. Morinobu, Sept 838–840

Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment [CME]. Saxena, Jan 21–27
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. de Haan, Feb 104–107
Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. Denys, Aug 700–703
Quetiapine augmentation of sertraline in obsessive-compulsive disorder [letter]. Francobandiera, Nov 1046–1047
Recent findings in the genetics of OCD. Pato, Suppl 6, 30–33
Refractory obsessive-compulsive disorder: state-of-the-art treatment. Hollander, Suppl 6, 20–29
Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. Albert, Nov 1004–1009

Olanzapine

Comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. Zajecka, Dec 1148–1155
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. Gianfrancesco, Oct 920–930
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. Kim K-S, May 408–413
Eosinophilia associated with olanzapine [letter]. Mathias, Mar 246–247
Hyperinsulinemia in psychiatric patients treated with olanzapine [letter]. Cohn, Jan 75–76
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. de Haan, Feb 104–107
Olanzapine for cocaine craving and relapse prevention in 2 patients [letter]. Longo, July 595–596
Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis [letter]. Fawcett, Feb 169
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. Lindenmayer, Oct 931–935
Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study. Marangell, May 391–395
Olanzapine treatment for patients with schizophrenia and cocaine abuse [letter]. Tsuang, Dec 1180–1181
Open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. Matthews, Dec 1164–1170
Retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. Meyer JM, May 425–433
Risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. Caro, Dec 1135–1139
Severe hypertriglyceridemia associated with olanzapine [letter]. Stoner, Oct 948–949
Sleep-related eating disorder induced by olanzapine [letter]. Paquet, July 597
Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. Lee C-T, July 569–576
Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia [letter]. Levy, Nov 1045

Opioid Abuse

Characteristics of opiate dependent patients who attempt suicide. Roy, May 403–407

Outpatients

Anger and aggression in psychiatric outpatients. Posternak, Aug 665–672
Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia [CME]. Hofer, Jan 49–53

Oxcarbazepine

Oxcarbazepine-induced syndrome of inappropriate secretion of antidiuretic hormone [letter]. Cilli, Aug 742

Palinopsia

Palinopsia and paroxetine withdrawal [letter]. Terao, Apr 368

Panic

Is bipolar disorder specifically associated with panic disorder in youths? [CME] Birmaher, May 414–419
Management of panic disorder. Sheehan, Suppl 14, 17–21
Randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. Kampman, Sept 772–777
Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. Versiani, Jan 31–37
Smoking cessation and panic attacks: a report of 2 cases [letter]. Vessicchio, July 594–595

Parkinson's Disease

Effect of reboxetine on depression in Parkinson's disease patients. Lemke, Apr 300–304
Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. Fernandez, June 513–515
Valproate-induced parkinsonism in a demented elderly patient [letter]. Iijima, Jan 75

Paroxetine

Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. Kennedy, Mar 181–186
Double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. Kim SW, June 501–507
Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans. Polsky, Feb 156–164
Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. Golden RN, July 577–584
Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. Normann, Apr 337–344
Palinopsia and paroxetine withdrawal [letter]. Terao, Apr 368
Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. Cassano, May 396–402
Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. Stein DJ, Feb 152–155
Randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Liebowitz, Jan 66–74
Randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. Kampman, Sept 772–777
Randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. Vieta, June 508–512
Surprising results in the study of paroxetine for generalized anxiety disorder [letter]. Ballas; Pollack reply, June 536–537
Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. Miner, Mar 232–240

Pathological Gambling

Double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. Kim SW, June 501–507
Lithium and valproate treatment of pathological gambling: a randomized single-blind study. Pallanti, July 559–564
Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. Pallanti, Nov 1034–1039
Open-label study of citalopram in the treatment of pathological gambling. Zimmerman, Jan 44–48

Pedophilia

Personality impairment in male pedophiles. Cohen LJ, Oct 912–919

Personality

Personality impairment in male pedophiles. Cohen LJ, Oct 912–919

Phenylpropanolamine

Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. Borovicka, Apr 345–348

Phototherapy

Randomized trial of the efficacy of bright-light exposure and aerobic exercise on depressive symptoms and serum lipids [CME]. Leppämäki, Apr 316–321

Pisa Syndrome

Risperidone-induced Pisa syndrome [letter]. Harada, Feb 166

Polycystic Ovary Syndrome

Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. O'Donovan, Apr 322–330

Positron Emission Tomography

Imaging substance P receptors (NK_1) in the living

human brain using positron emission tomography. Hargreaves, Suppl 11, 18–24

Posttraumatic Stress Disorder

Design and interpretability of findings in a family study to investigate posttraumatic stress disorder [letter]. Droege; Dierker reply, June 537–538

EMDR for women who experience traumatic events [letter]. Peterson; Foa reply, Nov 1047–1048

Fluoxetine versus placebo in posttraumatic stress disorder. Martenyi, Mar 199–206

Gabapentin and PTSD [letter]. Berigan, Aug 744

Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. Berlant, Jan 15–20

Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Rapaport, Jan 59–65

Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. Raskind, July 565–568

Sleep dynamic therapy for Cerro Grande fire evacuees with posttraumatic stress symptoms: a preliminary report. Krakow, Aug 673–684

Prazosin

Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. Raskind, July 565–568

Prediction

Predictors of noncompliance in patients with schizophrenia [CME]. Perkins, Dec 1121–1128

Pregnancy

Depression during pregnancy: diagnosis and treatment options. Nonacs, Suppl 7, 24–30

Premenstrual Dysphoria

Diagnosis and treatment of premenstrual dysphoria. Eriksson, Suppl 7, 16–23

Priapism

Exacerbation of idiopathic priapism with risperidone-citalopram combination [letter]. Freudenreich, Mar 249–250

Primary Care

Generalized anxiety and depression in primary care: prevalence, recognition, and management. Wittchen, Suppl 8, 24–34

Generalized anxiety disorder in primary care: emerging issues in management and treatment. Culpepper, Suppl 8, 35–42

Prolactin

Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. Kim K-S, May 408–413

Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. Maguire, Suppl 4, 56–62

Prostatodynia

Randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Turkington, Sept 778–781

Psychotropic Drugs

Can psychopharmacologic treatments that relieve symptoms also prevent disease progression? [Brainstorms] Stahl, Nov 961–962

Safety Profiles of Mood Stabilizers, Antipsychotics, and Broad-Spectrum Psychotropics. Suppl 4, 1–65

Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. Ohayon, Sept 817–825

Quality of Life

Comparison between the effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program [CME]. Meyer PS, Feb 108–116

Effects of antidepressant treatment on the quality of daily life: an experience sampling study [CME]. Barge-Schaapveld, June 477–485

Quetiapine

Case report of quetiapine-related tic-like symptoms [letter]. Huang, Dec 1184–1185

Clinical use of quetiapine in disease states other than schizophrenia. Adityanjee, Suppl 13, 32–38

Delusions associated with quetiapine-related weight redistribution [letter]. Wirshing DA, Mar 247–248

Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. Sajatovic, Dec 1156–1163

Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. Nasrallah, Suppl 13, 12–20

High degree of tolerability for monotherapy with high doses of quetiapine: a case report [letter]. Bobes, Nov 1048–1049

Introduction. Quetiapine: a 5-year update. Lieberman, Suppl 13, 3–4

Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. Denys, Aug 700–703

Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. Tauscher-Wisniewski, Nov 992–997

Quetiapine augmentation of sertraline in obsessive-compulsive disorder [letter]. Francobandiera, Nov 1046–1047

Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. Fernandez, June 513–515

Quetiapine Fumarate: A 5-Year Review. Suppl 13, 1–40

Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. Nemeroff, Suppl 13, 5–11

Use of quetiapine in children and adolescents. Findling, Suppl 13, 27–31

Use of quetiapine in elderly patients. Tariot, Suppl 13, 21–26

Racial Issues

Differential prescription of maintenance antipsychotics to African American and white patients with new-onset bipolar disorder. Fleck, Aug 658–664

Rash

Lamotrigine and rash: scratching beneath the surface [commentary]. Labiner, Nov 1010–1011

Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. Calabrese, Nov 1012–1019

Reboxetine

Effect of reboxetine on depression in Parkinson's disease patients. Lemke, Apr 300–304

Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. Versiani, Jan 31–37

Restless Legs Syndrome

Restless legs syndrome induced by mirtazapine [letter]. Ağargün, Dec 1179

Retraction

Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. Feifel, 2000;61:909–911. Retraction, Feb 169

Risperidone

Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. Margolese, Nov 1040–1044

Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. Gianfrancesco, Oct 920–930

Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. Sajatovic, Dec 1156–1163

Exacerbation of idiopathic priapism with risperidone-citalopram combination [letter]. Freudenreich, Mar 249–250

Naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in New York state inpatients. Javitt, July 585–590

No complications with risperidone treatment before and throughout pregnancy and during the nursing period [letter]. Ratnayake, Jan 76–77

Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. de Haan, Feb 104–107

Open pilot study combining risperidone and a selective serotonin reuptake Inhibitor as initial antidepressant therapy. Hirose, Aug 733–736

Resolution of hyperglycemia on risperidone discontinuation: a case report [letter]. Mallya, May 453–454

Retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. Meyer JM, May 425–433

Risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. Caro, Dec 1135–1139

Risperidone-induced Pisa syndrome [letter]. Harada, Feb 166

Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. Merlo, Oct 885–891

Treatment of borderline personality disorder with risperidone. Rocca, Mar 241–244

Schizoaffective Disorder

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Kane, Sept 763–771

Vitamin B_6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study. Lerner, Jan 54–58

Schizophrenia

Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia [CME]. Hofer, Jan 49–53

Carbamazepine augmentation for schizophrenia: how good is the evidence? Leucht, Mar 218–224

Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. Umbricht, May 420–424

Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. Kim K-S, May 408–413
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Kane, Sept 763–771
Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. Nasrallah, Suppl 13, 12–20
Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. Emsley, Jan 9–14
Injection of depot antipsychotic medications in patients with schizophrenia [letter]. Fleishman; Bloch reply, Sept 840–842
Introduction: cardiovascular and metabolic risks associated with schizophrenia and antipsychotic drug treatment. Meltzer, Suppl 9, 3–4
Management of weight gain in patients with schizophrenia. Aquila, Suppl 4, 33–36
No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. Barak, Feb 117–119
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. Lindenmayer, Oct 931–935
Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. Borovicka, Apr 345–348
Predictors of noncompliance in patients with schizophrenia [CME]. Perkins, Dec 1121–1128
Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature [CME]. Lacro, Oct 892–909
Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. Tauscher-Wisniewski, Nov 992–997
Risk of cardiovascular disease and sudden death in schizophrenia. Davidson, Suppl 9, 5–11. Correction, Aug 744
Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. Merlo, Oct 885–891
Smoking in bipolar and schizophrenic patients [letter]. de Leon; Einat reply, Apr 368–369
Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia [letter]. Levy, Nov 1045
28-Week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. Hirsch, June 516–523
Vitamin B_6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study. Lerner, Jan 54–58

Selective Serotonin Reuptake Inhibitors

Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. Maina, Jan 38–43
Open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. Hirose, Aug 733–736
Overview: the use of SSRIs in depressive disorders specific to women. Altshuler, Suppl 7, 3–8
Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. Denys, Aug 700–703
Sexual functioning and SSRIs. Fava, Suppl 5, 13–16
Topiramate treatment for SSRI-induced weight gain in anxiety disorders. Van Ameringen, Nov 981–984

Self-Mutilation

Limbic leucotomy in self-mutilation [letter]. Dean; Price reply, Dec 1181–1182

Sensory Gating

Normal P50 gating in children with autism [CME]. Kemner, Mar 214–217

Serotonin

Case of ziprasidone-induced mania and the role of 5-HT_{2A} in mood changes induced by atypical antipsychotics [letter]. Lu BY, Dec 1185–1186

Sertraline

Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans. Polsky, Feb 156–164
Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Rapaport, Jan 59–65
Quetiapine augmentation of sertraline in obsessive-compulsive disorder [letter]. Francobandiera, Nov 1046–1047
Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. Miner, Mar 232–240

Sexual Function

After sildenafil: bridging the gap between pharmacologic treatment and satisfying sexual relationships. Leiblum, Suppl 5, 17–22
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. Kennedy, Mar 181–186
Exploring the relationship between depression and erectile dysfunction in aging men. Seidman, Suppl 5, 5–12
Fluoxetine-induced sexual dysfunction reversed by loratadine [letter]. Brubaker, June 534
Introduction. Treating sexual dysfunction: psychiatry's role in the age of sildenafil. Roose, Suppl 5, 3–4
Prevalence of sexual dysfunction among newer antidepressants. Clayton, Apr 357–366
Role of receptor binding profiles in antidepressant-induced sexual dysfunction [letter]. Haberfellner; Montejo reply, Feb 168
Sexual function and behavior in social phobia. Bodinger, Oct 874–879
Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. Zajecka, Aug 709–716
Sexual functioning and SSRIs. Fava, Suppl 5, 13–16

Sibutramine

Open-label trial of sibutramine in obese patients with binge-eating disorder. Appolinario, Jan 28–30
Organic hypomania secondary to sibutramine-citalopram interaction [letter]. Benazzi, Feb 165

Sildenafil

After sildenafil: bridging the gap between pharmacologic treatment and satisfying sexual relationships. Leiblum, Suppl 5, 17–22
Introduction. Treating sexual dysfunction: psychiatry's role in the age of sildenafil. Roose, Suppl 5, 3–4
Sildenafil advertising and the realities of sildenafil treatment [letter]. Sigmund, Dec 1183

Sleep

Awakening to the psychopharmacology of sleep and arousal: novel neurotransmitters and wake-promoting drugs [BRAINSTORMS]. Stahl, June 467–468
Obsessive-compulsive disorder with non–24-hour sleep-wake syndrome [letter]. Morinobu, Sept 838–840
Sleep dynamic therapy for Cerro Grande fire evacuees with posttraumatic stress symptoms: a preliminary report. Krakow, Aug 673–684

Sleep Apnea

Sleep apnea associated with antipsychotic-induced obesity [letter]. Wirshing, Apr 369–370

Smoking

Smoking cessation and panic attacks: a report of 2 cases [letter]. Vessicchio, July 594–595
Smoking in bipolar and schizophrenic patients [letter]. de Leon; Einat reply, Apr 368–369

Social Anxiety Disorder

Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. Stein DJ, Feb 152–155
Randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Liebowitz, Jan 66–74
Sexual function and behavior in social phobia. Bodinger, Oct 874–879
Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. Stein DJ, Suppl 6, 12–19

Somatoform Disorders

Predominance of anger in depressive disorders compared with anxiety disorders and somatoform disorders [CME]. Koh, June 486–492

Stereoisomers

Mirror, mirror on the wall, which enantiomer is fairest of them all? [BRAINSTORMS] Stahl, Aug 656–657

Substance Abuse

Association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study [CME]. Goldberg, Sept 791–795
Sex differences in depressed substance abusers [CME]. Sinha, July 616–627

Substance P Antagonists

Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK_1). Santarelli, Suppl 11, 11–17
Clinical experience with substance P receptor (NK_1) antagonists in depression. Krishnan, Suppl 11, 25–29
Imaging substance P receptors (NK_1) in the living human brain using positron emission tomography. Hargreaves, Suppl 11, 18–24
Introduction. Pathophysiology of depression: the emerging role of substance P. Krishnan, Suppl 11, 4–5

Neurobiology of substance P and the NK_1 receptor. Mantyh, Suppl 11, 6–10
Suicide
Burning charcoal: an indigenous method of committing suicide in Hong Kong. Leung, May 447–450
Characteristics of opiate dependent patients who attempt suicide. Roy, May 403–407
Longitudinal view of triggers and thresholds of suicidal behavior in depression [CME]. Pezawas, Oct 866–873
Risk factors for completed suicide in bipolar disorder. Tsai, June 469–476
Switching
Antidepressant dosing and switching guidelines: focus on nefazodone. Zajecka, Suppl 1, 42–47
Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. Lee C-T, July 569–576
Syndrome of Inappropriate Secretion of Antidiuretic Hormone
Oxcarbazepine-induced syndrome of inappropriate secretion of antidiuretic hormone [letter]. Cilli, Aug 742
Tardive Dyskinesia
Clozapine and tardive dyskinesia [letter]. Kumet, Feb 167–168
Testosterone
Testosterone therapy in late-life major depression in males. Perry, Dec 1096–1101
Topiramate
Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. Berlant, Jan 15–20
Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia [letter]. Levy, Nov 1045
Topiramate treatment for SSRI-induced weight gain in anxiety disorders. Van Ameringen, Nov 981–984
Tourette's Disorder
Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. Margolese, Nov 1040–1044
Transcranial Magnetic Stimulation
Switch to mania after slow rTMS of the right prefrontal cortex [letter]. Ella, Mar 249
Trauma see also Posttraumatic Stress Disorder
Hypnotic medication in the aftermath of trauma [letter]. Mellman, Dec 1183–1184
Traumatic Grief
Traumatic grief treatment: case histories of 4 patients. Harkness, Dec 1113–1120
United Kingdom
Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. Kornegay, Sept 758–762
Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. Ohayon, Sept 817–825
Urinary Incontinence
Urinary incontinence with mirtazapine [letter]. Kunwar, May 454
Vagus Nerve Stimulation
Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: a pilot study. Sjögren, Nov 972–980
Valproate
Carbamazepine and valproate in the maintenance treatment of bipolar disorder. Keck, Suppl 10, 13–17
Hemodialysis in the treatment of valproic acid overdose [letter]. Kroll, Jan 78–79
Lithium and valproate treatment of pathological gambling: a randomized single-blind study. Pallanti, July 559–564
Valproate-induced parkinsonism in a demented elderly patient [letter]. Iijima, Jan 75
Vantaa Depression Study
Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study. Melartin, Feb 126–134
Venlafaxine
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. Kennedy, Mar 181–186
Hypokalemia with venlafaxine [letter]. Shang, Nov 1049–1050
Randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. Vieta, June 508–512
Rapid onset of antidepressant activity with venlafaxine [letter]. Weisler; Chesen reply, June 534–536
Venlafaxine in a patient with idiopathic leukopenia and mirtazapine-induced severe neutropenia [letter]. Anghelescu, Sept 838
Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. Malhotra, Sept 802–806
Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. Albert, Nov 1004–1009
Vitamin B_6
Vitamin B_6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study. Lerner, Jan 54–58
Wakefulness
Psychopharmacology of wakefulness: pathways and neurotransmitters [BRAINSTORMS]. Stahl, July 551–552
Weight
Correlates of overweight and obesity in 644 patients with bipolar disorder. McElroy, Mar 207–213
Delusions associated with quetiapine-related weight redistribution [letter]. Wirshing DA, Mar 247–248
Management of weight gain in patients with schizophrenia. Aquila, Suppl 4, 33–36
Mechanisms of weight gain induced by antipsychotic drugs [letter]. Baptista, Mar 245–246
Medical management of obesity associated with mental disorders. Malhotra, Suppl 4, 24–32
Metabolic syndrome: psychopharmacologists should weigh the evidence for weighing the patient [BRAINSTORMS]. Stahl, Dec 1094–1095
No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. Barak, Feb 117–119
Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. Borovicka, Apr 345–348
Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. Fagiolini, June 528–533
Six-year perspectives on the safety and tolerability of nefazodone. Dunner, Suppl 1, 32–41
Sleep apnea associated with antipsychotic-induced obesity [letter]. Wirshing, Apr 369–370
Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia [letter]. Levy, Nov 1045
Topiramate treatment for SSRI-induced weight gain in anxiety disorders. Van Ameringen, Nov 981–984
Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. Malhotra, Sept 802–806
Women
Alternative treatments for depression: empirical support and relevance to women [CME]. Manber, July 628–640
Chronic depression in women [CME]. Kornstein, July 602–609
Depression during pregnancy: diagnosis and treatment options. Nonacs, Suppl 7, 24–30
Diagnosis and treatment of premenstrual dysphoria. Eriksson, Suppl 7, 16–23
Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. Frankenburg, May 442–446
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. Kim K-S, May 408–413
EMDR for women who experience traumatic events [letter]. Peterson; Foa reply, Nov 1047–1048
Epidemiology of depression throughout the female life cycle. Burt, Suppl 7, 9–15
Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. Rasgon, Suppl 7, 45–48
Impact of reproductive events on the course of bipolar disorder in women [CME]. Freeman, Apr 284–287
Introduction: women and depression. Mazure, July 600–609
Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. O'Donovan, Apr 322–330
No complications with risperidone treatment before and throughout pregnancy and during the nursing period [letter]. Ratnayake, Jan 76–77
Overview: the use of SSRIs in depressive disorders specific to women. Altshuler, Suppl 7, 3–8
Serum bupropion levels in 2 breastfeeding mother-infant pairs. Baab, Oct 910–911
Treatment of postpartum depression: minimizing infant exposures. Newport, Suppl 7, 31–44
What research suggests for depressed women with children [CME]. Weissman, July 641–647
Ziprasidone
Case of ziprasidone-induced mania and the role of $5\text{-}HT_{2A}$ in mood changes induced by atypical antipsychotics [letter]. Lu BY, Dec 1185–1186
28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. Hirsch, June 516–523

Journal of Clinical Psychiatry

Author Index to Volume 63: January 2002 Through December 2002

Acker S see Cohen LJ
Ackerl S see Pezawas L
Adityanjee, Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia. Suppl 13, 32–38
Adler LA, Chua HC. Management of ADHD in adults. Suppl 12, 29–35
Adli M, Berghöfer A, Linden M, Helmchen H, Müller-Oerlinghausen B, Mackert A, Stamm T, Bauer M. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study [CME]. Sept 782–790
Adson DE see Kim SW
Ağargün MY, Kara H, Özbek H, Tombul T, Ozer OA. Restless legs syndrome induced by mirtazapine [letter]. Dec 1179
Aguglia E see Albert U; Hirschfeld RMA
Ahokas A, Kaukoranta J, Wahlbeck K, Aito M. Reply to Soares CN: Efficacy of 17β-estradiol on depression: is estrogen deficiency really necessary? [letter] May 451–452
Aito M see Ahokas A
Aizenberg D see Bodinger L
Akiskal HS see Perugi G
Albert U, Aguglia E, Maina G, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. Nov 1004–1009
Alda M see Duffy A; Grof P
Algun E see Cilli AS
Ali MW see Kane JM
Allen AJ, Michelson D. Drug development process for a product with a primary pediatric indication. Suppl 12, 44–49
Allen JJB see Manber R
Allingham BH see Javitt DC
Almeida OP see Soares CN
Altshuler LL. Overview: the use of SSRIs in depressive disorders specific to women. Suppl 7, 3–8
Altshuler LL, Gitlin MJ, Mintz J, Leight KL, Frye MA. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. Sept 807–811
Altshuler LL see McElroy SL; Rasgon NL
Amore M see Hirschfeld RMA
Andersch B see Eriksson E
Andersen AE see Perry PJ
Anghelescu I, Klawe C, Dahmen N. Venlafaxine in a patient with idiopathic leukopenia and mirtazapine-induced severe neutropenia [letter]. Sept 838
Annable L see Margolese HC
Appolinario JC, Godoy-Matos A, Fontenelle LF, Carraro L, Cabral M, Vieira A, Coutinho W. Open-label trial of sibutramine in obese patients with binge-eating disorder. Jan 28–30
Aquila R. Management of weight gain in patients with schizophrenia. Suppl 4, 33–36
Arango C see Bobes J
Arnold A see Newport DJ
Arnold LM, McElroy SL, Hudson JI, Welge JA, Bennett AJ, Keck PE Jr. Placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. Nov 1028–1033
Arnow BA see Zajecka J
Aschauer H see Pezawas L
Ashby CR see Hirose S
Ashcraft JC see Wirshing DA
Asnis GM see Gabbay V
Axelson D see Birmaher B
Azizian K see Wirshing DA
Baab SW, Peindl KS, Piontek CM, Wisner KL. Serum bupropion levels in 2 breastfeeding mother-infant pairs. Oct 910–911
Baer L see Greist JH
Bahk W-M see Kim K-S
Bailey L see Dunner DL
Baker GB see Kennedy SH
Ballard CG, O'Brien JT, Reichelt K, Perry EK. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with *Melissa*. July 553–558
Ballas CA. Surprising results in the study of paroxetine for generalized anxiety disorder [letter with reply]. June 536
Ballon JS see Wirshing DA
Baptista T. Mechanisms of weight gain induced by antipsychotic drugs [letter]. Mar 245–246
Barak Y. No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. Feb 117–119
Baral I see Price BH
Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. Aug 737–741
Barge-Schaapveld DQCM, Nicolson NA. Effects of antidepressant treatment on the quality of daily life: an experience sampling study [CME]. June 477–485
Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. Suppl 12, 10–15
Barkley RA. Psychosocial treatments for attention-deficit/hyperactivity disorder in children. Suppl 12, 36–43
Barkley RA see Saylor KE
Bascaran M-T see Bobes J
Bass KI see Clayton AH
Bauer M see Adli M
Bauer MS see Polsky D
Bäuml J see Hirsch SR
Bech P see Montgomery SA
Becoña E see de Leon J
Beesdo K see Wittchen H-U
Begley AE see Joo JH
Bellew KM see Pollack MH
Benabarre A see Vieta E
Benazzi F. Clinical features of bipolar depression [letter with reply]. Jan 77–78
Benazzi F. High frequency of residual depressive symptoms in bipolar II disorder: the need for a better treatment [letter with reply]. Nov 1045–1046
Benazzi F. Organic hypomania secondary to sibutramine-citalopram interaction [letter]. Feb 165
Benedetti A see Versiani M
Benjamin S. Review of Salloway SP, Malloy PF, Duffy JD (eds): *The Frontal Lobes and Neuropsychiatric Illness*. July 598
Benkelfat C see Hollander E
Ben-Menachem E see Sjögren MJC
Bennett AJ see Arnold LM
Berger G see Merlo MCG
Berghöfer A see Adli M
Berigan TR. Gabapentin and PTSD [letter]. Aug 744
Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. Jan 15–20
Berndt ER see Crown WH
Bernet W. Review of Schetky DH, Benedek EP (eds): *Principles and Practice of Child and Adolescent Forensic Psychiatry*. Oct 951
Bernstein CA. Review of Steiner M, Yonkers KA, Eriksson E (eds): *Mood Disorders in Women*. Apr 373
Beuk N see de Haan L
Biederman J see Spencer T; Spencer TJ
Bienstock CA see Hollander E
Bienvenu OJ see Nestadt G
Bird DC see O'Donovan C
Birmaher B, Kennah A, Brent D, Ehmann M, Bridge J, Axelson D. Is bipolar disorder specifically associated with panic disorder in youths? [CME] May 414–419
Birnbaum HG see Corey-Lisle PK
Black KJ. Review of Dougherty DD, Rauch SL (eds): *Psychiatric Neuroimaging Research: Contemporary Strategies*. Nov 1052

Blier P see Montgomery SA; Santarelli L
Bloch Y. Reply to Fleishman M: Injection of depot antipsychotic medications in patients with schizophrenia [letter]. Sept 840–842
Bobes J, Garcia-Portilla MP, Saiz PA, Bascaran M-T, Bousoño M, Arango C. High degree of tolerability for monotherapy with high doses of quetiapine: a case report [letter]. Nov 1048–1049
Bodinger L, Hermesh H, Aizenberg D, Valevski A, Marom S, Shiloh R, Gothelf D, Zemishlany Z, Weizman A. Sexual function and behavior in social phobia. Oct 874–879
Bogetto F see Albert U; Maina G; Rocca P
Bolden-Watson C see Clayton AH
Bond GR see Meyer PS
Borian FE see Ninan PT; Thase ME; Zajecka J
Borovicka MC, Fuller MA, Konicki PE, White JC, Steele VM, Jaskiw GE. Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. Apr 345–348
Bose A see Burke WJ
Bottonari KA see Matthews JD
Bougerol T see Llorca P-M
Bousoño M see Bobes J
Bowden CL. Introduction: long-term use of mood stabilizers in bipolar disorder. Suppl 10, 3–4
Bowden CL see Calabrese JR; Suppes T
Boyd JA see Wirshing DA
Boyer SK see Mallya A
Brady KT see Charney DS
Brawman-Mintzer O see Yonkers KA
Breen RB see Zimmerman M
Brenner R, Madhusoodanan S, Pawlowska M. Efficacy of continuation treatment with *Hypericum perforatum* in depression [letter]. May 455
Brent D see Birmaher B
Bridge J see Birmaher B
Brown EB see Martenyi F; Miner CM
Brown FW. Review of Conn DK, Herrmann N, Kaye A, Rewilak D, Schogt B: *Practical Psychiatry in the Long-Term Care Facility: A Handbook for Staff, 2nd Revised and Expanded ed.* June 541–542
Brubaker RV. Fluoxetine-induced sexual dysfunction reversed by loratadine [letter]. June 534
Brunson GH see Hales RE
Brusman-Lovins L see Malhotra S
Buermeyer CM see Saylor KE
Bullock KD see Koran LM
Burke MA see Fernandez HH
Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. Apr 331–336
Burnham DB see Pollack MH
Burt VK, Stein K. Epidemiology of depression throughout the female life cycle. Suppl 7, 9–15
Buse JB. Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. Suppl 4, 37–41
Bustamante V see Mellman TA
Buysse DJ see Fagiolini A
Bystritsky A see Saxena S
Cabral M see Appolinario JC
Calabrese JR, Shelton MD, Rapport DJ, Kimmel SE. Bipolar disorders and the effectiveness of novel anticonvulsants. Suppl 3, 5–9
Calabrese JR, Shelton MD, Rapport DJ, Kimmel SE, Elhaj O. Long-term treatment of bipolar disorder with lamotrigine. Suppl 10, 18–22
Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, Shelton MD, Goodwin FK, Frye MA, Kusumakar V. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. Nov 1012–1019
Calabrese JR see Ketter TA; Suppes T; Yatham LN
Campbell EC see Caroff SN
Campbell M see Van Ameringen M
Caro JJ, Ward A, Levinton C, Robinson K. Risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. Dec 1135–1139
Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. Suppl 4, 12–19
Carpenter D see Liebowitz MR
Carraro L see Appolinario JC
Carson WH see Kane JM
Cassano GB, Puca F, Scapicchio PL, Trabucchi M, for the Italian Study Group on Depression in Elderly Patients. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. May 396–402
Cassano G see Versiani M
Cassem EH see Price BH
Cavazzoni P see Duffy A; Grof P
Chae J-H see Kim K-S
Chakos M see Lindenmayer J-P
Charney DS, Grothe DR, Smith SL, Brady KT, Kaltsounis-Puckett J, Wright CW, Laird LK, Rush AJ. Overview of psychiatric disorders and the role of newer antidepressants. Suppl 1, 3–9
Chawla P see Mallya A
Chelminski I see Zimmerman M
Chen C-C see Tsai S-YM
Chesen CL, Gelenberg AJ. Reply to Weisler RH: Rapid onset of antidepressant activity with venlafaxine [letter]. June 535–536
Chouinard G see Levy E
Christensen BK see Tauscher-Wisniewski S
Chua HC see Adler LA
Chung WSD see Leung CM
Cienfuegos A see Javitt DC
Cilli AS, Algun E. Oxcarbazepine-induced syndrome of inappropriate secretion of antidiuretic hormone [letter]. Aug 742
Ciraulo DA. Review of Jenkins SC, Tinsley JA, Van Loon JA: *A Pocket Reference for Psychiatrists, 3rd ed.* Sept. 844–845
Citrome L see Lindenmayer J-P
Clagnaz P see Kobak KA
Clark JO see Krakow BJ
Clary CM see Greist JH; Rapaport MH
Claxton AJ see Corey-Lisle PK
Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue RMJ, Jamerson BD, Metz A. Prevalence of sexual dysfunction among newer antidepressants. Apr 357–366
Cluss PA see Kupfer DJ
Cocuzza E see Rocca P
Cohen H see Lerner V
Cohen LJ, McGeoch PG, Watras-Gans S, Acker S, Poznansky O, Cullen K, Itskovich Y, Galynker I. Personality impairment in male pedophiles. Oct 912–919
Cohen LS see Nonacs R; Soares CN
Cohen NL see Lam RW
Cohn TA, Remington G, Kameh H. Hyperinsulinemia in psychiatric patients treated with olanzapine [letter]. Jan 75–76
Colom F see Vieta E
Conde BJL see Lee C-T
Conners CK see Spencer T
Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ. Identification of a claims data "signature" and economic consequences for treatment-resistant depression. Aug 717–726
Corruble E see Llorca P-M
Cosgrove GR see Price BH
Coutinho W see Appolinario JC
Crismon ML see Suppes T
Crits-Christoph P see Ninan PT
Croft HA see Clayton AH
Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, Russell JM. Impact of treatment-resistant depression on health care utilization and costs [CME]. Nov 963–971
Cullen K see Cohen LJ
Culpepper L. Generalized anxiety disorder in primary care: emerging issues in management and treatment. Suppl 8, 35–42
Czobor P see Lindenmayer J-P
Dahmen N see Anghelescu I
D'Andrea V see Koran LM
Daniel DG. Review of Keltner NL, Folks DG: *Psychotropic Drugs, 3rd ed.* Apr 372
Danniau A see Llorca P-M
Darmandjian H see Wirshing DA
Daskalakis ZJ see Tauscher-Wisniewski S
David D see Mellman TA
Davidson M. Risk of cardiovascular disease and sudden death in schizophrenia. Suppl 9, 5–11. Correction, Aug 744
Davidson M see Meltzer HY
Davtyan C see Rasgon NL
Dean CE. Limbic leucotomy in self-mutilation [letter with reply]. Dec 1181–1182
de Castro AMR see García-Pando AC
de Haan L, Beuk N, Hoogenboom B, Dingemans P, Linszen D. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. Feb 104–107
DelBello MP see Fleck DE
de Leon J, Becoña E, Gurpegui M, Gonzalez-Pinto A, Diaz FJ. Association between high nicotine dependence and severe mental illness may be consistent across countries. Sept 812–816
de Leon J, Diaz FJ. Smoking in bipolar and schizophrenic patients [letter with reply]. Apr 368–369
de Leon J see Diaz FJ
Delgado PL see Hirschfeld RMA

Demitrack MA. Can monoamine-based therapies be improved? Suppl 2, 14–18
Demitrack MA see Detke MJ; Goldstein DJ
Denicoff KD see McElroy SL
Dennehy EB see Suppes T
Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. Aug 700–703
DeRosear L see Mallya A
Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. Apr 308–315
DeVane CL, Grothe DR, Smith SL. Pharmacology of antidepressants: focus on nefazodone. Suppl 1, 10–17
Dhavale D see McElroy SL
Diaz FJ, de Leon J. Excessive antipsychotic dosing in 2 U.S. state hospitals. Nov 998–1003
Diaz FJ see de Leon J
Dickson RA see Kim K-S; Tham JC
Dierker LC, Merikangas KR. Reply to Droege VM: Design and interpretability of findings in a family study to investigate posttraumatic stress disorder [letter]. June 538
Diner BC. Review of Rogers R, Shuman DW: *Conducting Insanity Evaluations, 2nd ed.* Feb 170–171
Dingemans P see de Haan L
Dion Y see Margolese HC
Dobie DJ see Raskind MA
Dolata D see Tew JD Jr
Dolder CR see Lacro JP
Donahue RMJ see Clayton AH
Dording CM see Matthews JD
Droege VM. Design and interpretability of findings in a family study to investigate posttraumatic stress disorder [letter with reply]. June 537–538
Dubé EM see Golden RN
Dubisar BM see Stoner SC
Duffy A, Alda M, Kutcher S, Cavazzoni P, Robertson C, Grof E, Grof P. Prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. Dec 1171–1178
Duffy A see Grof P
Dunkin JJ see Rasgon NL
Dunn LB see Lacro JP
Dunner DL. Review of Bezchlibnyk-Butler KZ, Jeffries JJ (eds): *Clinical Handbook of Psychotropic Drugs, 11th ed., revised.* Mar 254
Dunner DL, Laird LK, Zajecka J, Bailey L, Sussman N, Seabolt JL. Six-year perspectives on the safety and tolerability of nefazodone. Suppl 1, 32–41
Dunner DL see Thase ME; Zajecka J
Eder U see Hofer A
Ehmann M see Birmaher B
Einat H. Reply to de Leon: Smoking in bipolar and schizophrenic patients [letter]. Apr 369
Elam LC. Review of the Committee on Human Sexuality for the Group for the Advancement of Psychiatry: *Homosexuality and the Mental Health Professions: The Impact of Bias.* Jan 80–81
Elhaj O see Calabrese JR
Ella R, Zwanzger P, Stampfer R, Preuss UW, Müller-Siecheneder F, Möller H-J, Padberg F. Switch to mania after slow rTMS of the right prefrontal cortex [letter]. Mar 249
Elliott MA see Koran LM
Elman S see Rasgon NL
Emsley RA, Roberts MC, Rataemane S, Pretorius J, Oosthuizen PP, Turner J, Niehaus DJH, Keyter N, Stein DJ. Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. Jan 9–14
Endicott J see Rapaport MH
Epstein I see Tauscher-Wisniewski S
Eriksson E, Andersch B, Ho HP, Landén M, Sundblad C. Diagnosis and treatment of premenstrual dysphoria. Suppl 7, 16–23
Ernst CL, Goldberg JF. Reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. Suppl 4, 42–55
Ernst CL see Goldberg JF
Escalona PR see Lu BY
Fagiolini A, Frank E, Houck PR, Mallinger AG, Swartz HA, Buysse DJ, Ombao H, Kupfer DJ. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. June 528–533
Fairbanks LA see Rasgon NL
Farah A. Interferon-induced depression treated with citalopram [letter]. Feb 166–167
Faraone SV see Spencer TJ
Faries DE see Spencer T
Farmer RG. Review of Bogousslavsky J, Cummings JL (eds): *Behavior and Mood Disorders in Focal Brain Lesions.* Jan 81
Farmer RG. Review of Nutt D, Davidson JRT, Zohar J (eds): *Posttraumatic Stress Disorder: Diagnosis, Management, and Treatment.* Aug 746
Farrar CD see Stoner SC
Faruch M see Llorca P-M
Fava M. Somatic symptoms, depression, and antidepressant treatment [commentary]. Apr 305–307
Fava M, Rankin M. Sexual functioning and SSRIs. Suppl 5, 13–16
Fava M see Matthews JD
Fawcett RG. Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis [letter]. Feb 169
Feeny NC, Ronis RJ. Review of the American Psychiatric Association Task Force: *Handbook of Psychiatric Measures.* Mar 253
Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. 2000;61:909–911. Retraction. Feb 169
Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. June 513–515
Ferrier IN see Turkington D
Feusner J see Wirshing DA
Finder SG. Review of the Ethics Committee of the American Psychiatric Association: *Opinions of the Ethics Committee on the Principles of Medical Ethics With Annotations Especially Applicable to Psychiatry: 2001 Edition.* Nov 1053
Finder SG. Review of the Ethics Committee of the American Psychiatric Association: *The Principles of Medical Ethics With Annotations Especially Applicable to Psychiatry: 2001 Edition.* Nov 1053
Findling RL. Use of quetiapine in children and adolescents. Suppl 13, 27–31
Finkelstein S see Crown WH
Finlayson AJR. Review of Daley DC, Salloum IM (eds): *Clinician's Guide to Mental Illness.* Nov 1051–1052
Fins AI see Mellman TA
Fishel-Ingram PT. Review of Rickel AU, Wise TN: *Understanding Managed Care: An Introduction for Health Care Professionals.* Apr 373
Flacker JM, Ouslander J. Review of Spar JE, La Rue A: *Concise Guide to Geriatric Psychiatry, 3rd ed.* Sept 845
Fleck DE, Hendricks WL, DelBello MP, Strakowski SM. Differential prescription of maintenance antipsychotics to African American and white patients with new-onset bipolar disorder. Aug 658–664
Fleischhacker WW see Hofer A
Fleishman M. Injection of depot antipsychotic medications in patients with schizophrenia [letter with reply]. Sept 840–841
Foa EB. Reply to Peterson G: EMDR for women who experience traumatic events [letter]. Nov 1048
Folks DG. Review of Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr: *Principles and Practice of Psychopharmacotherapy, 3rd ed.* Aug 748
Fontenelle LF see Appolinario JC
Ford CV. Review of Tseng W-S, Streltzer J (eds): *Culture and Psychotherapy: A Guide to Clinical Practice.* Nov 1051
Fossion P see Paquet V
Francobandiera G. Quetiapine augmentation of sertraline in obsessive-compulsive disorder [letter]. Nov 1046–1047
Frank E see Fagiolini A; Harkness KL; Kupfer DJ; Mazure CM
Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. May 442–446
Frare F see Perugi G
Freeman MP, Smith KW, Freeman SA, McElroy SL, Kmetz GF, Wright R, Keck PE Jr. Impact of reproductive events on the course of bipolar disorder in women [CME]. Apr 284–287
Freeman MP see Kumet R
Freeman SA see Freeman MP
Freudenreich O. Exacerbation of idiopathic priapism with risperidone-citalopram combination [letter]. Mar 249–250
Friedman ES see Thase ME
Friedman JH see Fernandez HH
Frye MA see Altshuler LL; Calabrese JR; McElroy SL
Fuller MA see Borovicka MC
Gabbard GO. Review of Hornstein GA: *To Redeem One Person Is to Redeem the World: The Life of Frieda Fromm-Reichmann.* June 539–540

Gabbay V, O'Dowd MA, Asnis GM. Combined antidepressant treatment: a risk factor for switching in bipolar patients [letter with reply]. Apr 367
Galynker I see Cohen LJ
Gandolfo S see Maina G
García del Pozo J see García-Pando AC
García-Pando AC, García del Pozo J, Sánchez AS, Martín AV, de Castro AMR, Lucena MI. Hepatotoxicity associated with the new antidepressants. Feb 135–137
Garcia-Portilla MP see Bobes J
Garnham J see Grof P
Garver DL. Review of Schatzberg AF, Nemeroff CB (eds): *Essentials of Clinical Psychopharmacology.* June 539
Gastpar M see Hirschfeld RMA
Gekle W see Merlo MCG
Gelenberg AJ. Gratitude [editorial]. Jan 4–6
Gelenberg AJ see Chesen CL; Zajecka J
George TP see Vessicchio JC
Gergel I see Burke WJ
Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang R-h, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. Oct 920–930
Gillin JC. Review of Hobson JA: *The Dream Drugstore: Chemically Altered States of Consciousness.* June 540
Gitlin MJ see Altshuler LL
Glassman AH. Clinical management of cardiovascular risks during treatment with psychotropic drugs. Suppl 9, 12–17
Glassman AH see Meltzer HY
Gleason OC, Yates WR, Isbell MD, Philipsen MA. Open-label trial of citalopram for major depression in patients with hepatitis C. Mar 194–198
Glick HA see Polsky D
Gobbi G see Santarelli L
Goddard A see Pollack MH
Godoy-Matos A see Appolinario JC
Goikolea JM see Vieta E
Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder [CME]. 985–991
Goldberg JF, Whiteside JE. Association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study [CME]. Sept 791–795
Goldberg JF see Calabrese JR; Ernst CL
Golden G see Saxena S
Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dubé EM. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. July 577–584
Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. Mar 225–231
Goldstein DJ see Detke MJ
Goldstein J see Nemeroff CB
Goldstein MZ. Review of Stotland NL, Stewart DE (eds): *Psychological Aspects of Women's Health Care: The Interface Between Psychiatry and Obstetrics and Gynecology, 2nd ed.* May 456–457
Gonzales JS see Miner CM
Gonzalez-Pinto A see de Leon J
Goodwin FK. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. Suppl 10, 5–12
Goodwin FK see Calabrese JR
Gorman JM. Treatment of generalized anxiety disorder. Suppl 8, 17–23
Gothelf D see Bodinger L
Gourley M see Lu R
Grados MA see Nestadt G
Grant JBF see Turkington D
Grant JE, Kim SW. Open-label study of naltrexone in the treatment of kleptomania. Apr 349–356
Grant JE see Kim SW
Graves GR see O'Donovan C
Greden JF. Unmet need: what justifies the search for a new antidepressant? Suppl 2, 3–7
Greenberg BD see Hollander E
Greenberg PE see Corey-Lisle PK
Greist JH, Marks IM, Baer L, Kobak KA, Wenzel KW, Hirsch MJ, Mantle JM, Clary CM. Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control. Feb 138–145
Greist JH, Mundt JC, Kobak K. Factors contributing to failed trials of new agents: can technology prevent some problems? Suppl 2, 8–13
Griez E see Overbeek T
Grochocinski VJ see Kupfer DJ
Grof E see Duffy A; Grof P
Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, O'Donovan C, Alda M. Is response to prophylactic lithium a familial trait? Oct 942–947
Grof P see Duffy A
Grogg AL see Gianfrancesco FD
Grothe DR see Charney DS; DeVane CL
Grunze H see McElroy SL; Normann C
Gurpegui M see de Leon J
Haberfellner EM. Role of receptor binding profiles in antidepressant-induced sexual dysfunction [letter with reply]. Feb 168
Hales RE, Hilty DM, Brunson GH. Cost savings with nefazodone in treating depression. Suppl 1, 48–51
Han A see Tsuang J
Hantouche E see Perugi G
Harada K, Sasaki N, Ikeda H, Nakano N, Ozawa H, Saito T. Risperidone-induced Pisa syndrome [letter]. Feb 166
Hargreaves R. Imaging substance P receptors (NK_1) in the living human brain using positron emission tomography. Suppl 11, 18–24
Harkness KL, Shear MK, Frank E, Silberman RA. Traumatic grief treatment: case histories of 4 patients. Dec 1113–1120
Harmon RJ. Review of Shafii M (ed): *School Violence: Assessment, Management, Prevention.* Sept 843–844
Hartston HJ see Koran LM
Haskett RF see Tew JD Jr
Haukka JK see Leppämäki SJ
Hawley C see Hirschfeld RMA
Hayes JR see Detke MJ
Heiligenstein JH see Spencer T
Hellström PTO see Sjögren MJC
Helmchen H see Adli M
Hen R see Santarelli L
Hendricks WL see Fleck DE
Hendriks G-J see Kampman M
Henk HJ see Kobak KA
Henry C. Reply to Gabbay V: Combined antidepressant treatment: a risk factor for switching in bipolar patients [letter]. Apr 367–368
Hermesh H see Bodinger L
Hillard JR. Review of Ruiz P (ed): *Ethnicity and Psychopharmacology (Review of Psychiatry series, vol. 19).* May 459
Hilty DM see Hales RE
Hirose S, Ashby CR. Open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. Aug 733–736
Hirose S, Ashby CR. Immediate effect of intravenous diazepam in neuroleptic-induced acute akathisia: an open-label study. June 524–427
Hirsch MJ see Greist JH
Hirsch SR, Kissling W, Bäuml J, Power A, O'Connor R. 28-Week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. June 516–523
Hirschfeld RMA, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, Hawley C, Kasper S, Linden M, Massana J, Mendlewicz J, Möller H-J, Nemeroff CB, Saiz J, Such P, Torta R, Versiani M. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. Sept 826–837
Hirschfeld RMA see Suppes T; Zajecka J
Hixson L see Tew JD Jr
Ho HP see Eriksson E
Hodo DW. Review of Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP: *Combining Medication and Psychosocial Treatments for Addictions: The BRENDA Approach.* Oct 951–952
Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker WW. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia [CME]. Jan 49–53
Hofer H see Merlo MCG
Hoff DJ see Raskind MA
Höfler M see Wittchen H-U
Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, Ravizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, Zohar J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. Suppl 6, 20–29
Hollander E, Zohar J, Marazziti D. Introduction: exploring the boundaries of obsessive-compulsive disorder and other anxiety disorders. Suppl 6, 3–4
Hollander E see Pallanti S
Hollifield MA see Krakow BJ
Holman TL see Perry PJ
Honeder M see Hofer A
Hoogduin CAL see Kampman M
Hoogenboom B see de Haan L
Hörn M see Normann C
Hostetter A see Newport DJ

Houck PR see Fagiolini A; Kupfer DJ
Hoyer J see Wittchen H-U
Hsieh W see Tsuang J
Huang S-C, Lai T-J, Tsai S-J. Case report of quetiapine-related tic-like symptoms [letter]. Dec 1184–1185
Hudson JI see Arnold LM
Hummel B see Normann C
Hummer M see Hofer A
Hunter B see Stein DJ
Hurley AD see Lu R
Hurme J see Leppämäki SJ
Iijima M. Valproate-induced parkinsonism in a demented elderly patient [letter]. Jan 75
Ikeda H see Harada K
Ingenito GG see Kane JM
Irvin R see Matthews JD
Isbell MD see Gleason OC
Ismail MS see Tariot PN
Isometsä ET see Melartin TK
Italian Study Group on Depression in Elderly Patients see Cassano GB
Itskovich Y see Cohen LJ
Iyengar MK see Pollack MH
Jagsch R see Pezawas L
Jamerson BD see Clayton AH
Jamhour NJ see Barbee JG
Jaskiw GE see Borovicka MC
Javitt DC, Cienfuegos A, Miniati M, Silipo G, Levine J, Allingham BH, Robinson J. Naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in New York state inpatients. July 585–590
Jenike MA see Price BH
Jensen P see Weissman MM
Jeste DV see Lacro JP
Jick H see Kornegay CJ
Joffe H see Soares CN
Johnson CR see Marangell LB
Johnston LG see Krakow BJ
Jones C see Tauscher-Wisniewski S
Jonsson MAG see Sjögren MJC
Joo JH, Lenze EJ, Mulsant BH, Begley AE, Weber EM, Stack JA, Mazumdar S, Reynolds CF III, Pollock BG. Risk factors for falls during treatment of late-life depression. Oct 936–941
Joseph DI. Review of Maris RW, Berman AL, Silverman MM: *Comprehensive Textbook of Suicidology.* Aug 745–746
Jun T-Y see Kim K-S
Kaltsounis-Puckett J see Charney DS
Kameh H see Cohn TA
Kampman M, Keijsers GPJ, Hoogduin CAL, Hendriks G-J. Randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. Sept 772–777
Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Sept 763–771
Kane JM see Umbricht DS
Kaplan BJ, Simpson JSA. Reply to Pies R: Role of micronutrients as possible mood-stabilizing agents [letter]. Aug 742–744
Kaptsan A see Lerner V
Kapur S see Tauscher-Wisniewski S
Kara H see Ağargün MY
Kasper S see Hirschfeld RMA; Pezawas L
Katzelnick DJ see Kobak KA
Kaukoranta J see Ahokas A
Kawashima T, Yamada S. Delirium caused by donepezil: a case study [letter]. Mar 250–251
Keck PE Jr, McElroy SL. Carbamazepine and valproate in the maintenance treatment of bipolar disorder. Suppl 10, 13–17
Keck PE Jr, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. Suppl 4, 3–11
Keck PE Jr see Arnold LM; Freeman MP; McElroy SL; Suppes T
Keijsers GPJ see Kampman M
Keller MB. Foreword: Global Research in Anxiety and Depression (GRAD) Network Consensus Conference. Suppl 8, 3
Keller MB. Long-term clinical course of generalized anxiety disorder. Suppl 8, 11–16
Keller MB see Ninan PT; Schatzberg AF; Thase ME; Zajecka J
Kemmler G see Hofer A
Kemner C, Oranje B, Verbaten MN, van Engeland H. Normal P50 gating in children with autism [CME]. Mar 214–217
Kennah A see Birmaher B
Kennedy SH, McCann SM, Masellis M, McIntyre RS, Raskin J, McKay G, Baker GB. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. Mar 181–186
Kennedy SH see Lam RW
Kertz B see Marangell LB
Kessler RC, Wittchen H-U. Patterns and correlates of generalized anxiety disorder in community samples. Suppl 8, 4–10
Kessler RC see Wittchen H-U
Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. Feb 146–151
Ketter TA, Wang PW. Predictors of treatment response in bipolar disorders: evidence from clinical and brain imaging studies. Suppl 3, 21–25
Keyter N see Emsley RA
Khan R see Stoner SC
Kim CH see Koh KB
Kim D-J see Kim K-S
Kim K-S, Pae C-U, Chae J-H, Bahk W-M, Jun T-Y, Kim D-J, Dickson RA. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. May 408–413
Kim SW, Grant JE, Adson DE, Shin YC, Zaninelli R. Double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. June 501–507
Kim SW see Grant JE
Kimmel SE see Calabrese JR
King KH see Malhotra S
Kinkead B see Nemeroff CB
Kirshner HS. Review of Mesulam M-M (ed): *Principles of Behavioral and Cognitive Neurology, 2nd ed.* Jan 82
Kissling W see Hirsch SR; Leucht S
Klawe C see Anghelescu I
Klein DN see Thase ME
Klein E. Role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation. Suppl 14, 27–33
Kmetz GF see Freeman MP
Kobak K see Greist JH
Kobak KA, Taylor LvH, Katzelnick DJ, Olson N, Clagnaz P, Henk HJ. Antidepressant medication management and health plan employer data information set (HEDIS) criteria: reasons for nonadherence. Aug 727–732
Koh KB, Kim CH, Park JK. Predominance of anger in depressive disorders compared with anxiety disorders and somatoform disorders [CME]. June 486–492
Koke SC see Martenyi F
Konicki PE see Borovicka MC
Kopelowicz A. Review of Warner R: *The Environment of Schizophrenia: Innovations in Practice, Policy and Communications.* Apr 374
Koplewicz HS see McCracken JT
Koran LM, Bullock KD, Hartston HJ, Elliott MA, D'Andrea V. Citalopram treatment of compulsive shopping: an open-label study. Aug 704–708
Koran LM see Hollander E; Pallanti S
Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. Sept 758–762
Kornstein SG. Chronic depression in women [CME]. July 602–609
Kornstein SG see Ninan PT; Thase ME; Zajecka J
Kotler M see Lerner V
Krakow BJ, Melendrez DC, Johnston LG, Clark JO, Santana EM, Warner TD, Hollifield MA, Schrader R, Sisley BN, Lee SA. Sleep dynamic therapy for Cerro Grande fire evacuees with posttraumatic stress symptoms: a preliminary report. Aug 673–684
Kramer T. Review of Dewan NA, Lorenzi NM, Riley RT, Bhattacharya SR (eds): *Behavioral Healthcare Informatics (Health Informatics Series).* Aug 745
Kratochvil CJ see Spencer T; Wernicke JF
Krause P see Wittchen H-U
Krishnan KRR. Clinical experience with substance P receptor (NK_1) antagonists in depression. Suppl 11, 25–29
Krishnan KRR. Introduction. Pathophysiology of depression: the emerging role of substance P. Suppl 11, 4–5
Kroeker G see Yatham LN
Kroll P, Nand C. Hemodialysis in the treatment of valproic acid overdose [letter]. Jan 78–79
Kumar R see Stein DJ
Kumet R, Freeman MP. Clozapine and tardive dyskinesia [letter]. Feb 167–168
Kunwar A, Virk S, Masand PS. Urinary incontinence with mirtazapine [letter]. May 454
Kuo C-J see Tsai S-YM
Kupfer DJ. Reply to Benazzi F: High frequency of residual depressive symptoms in bipolar II disorder: the need for a better treatment [letter]. Nov 1046

Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA. Demographic and clinical characteristics of individuals in a bipolar disorder case registry [CME]. Feb 120–125
Kupfer DJ see Fagiolini A
Kupka R see McElroy SL
Kusumakar V. Antidepressants and antipsychotics in the long-term treatment of bipolar disorder. Suppl 10, 23–28
Kusumakar V see Calabrese JR; O'Donovan C; Yatham LN
Kutcher S see Duffy A
Kwentus J. Review of The American Psychiatric Association Council on Aging Committee on Long-Term Care and Treatment of the Elderly. Greene JA, Loebel P (eds): *Manual of Nursing Home Practice for Psychiatrists.* Aug 747–748
Labiner DM. Lamotrigine and rash: scratching beneath the surface [commentary]. Nov 1010–1011
Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature [CME]. Oct 892–909
Lader MH see **Ohayon MM**
Lai T-J see Huang S-C
Laird LK see Charney DS; Dunner DL; Schatzberg AF
Lam RW, Wan DDC, Cohen NL, Kennedy SH. Combining antidepressants for treatment-resistant depression: a review [CME]. Aug 685–693
Lamps CA. Review of Eth S (ed): *PTSD in Children and Adolescents.* June 541
Landén M see Eriksson E
Latour G see Merlo MCG
Leadbetter RA see Clayton AH
Leckband SG see Lacro JP
Lee C-T, Conde BJL, Mazlan M, Visanuyothin T, Wang A, Wong MMC, Walker DJ, Roychowdhury SM, Wang H, Tran PV. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. July 569–576
Lee H-C see Tsai S-YM
Lee MA. Review of McEvoy JP: *Guide to Assessment Scales in Schizophrenia.* May 458
Lee SA see Krakow BJ
Leiblum SR. After sildenafil: bridging the gap between pharmacologic treatment and satisfying sexual relationships. Suppl 5, 17–22
Leight KL see Altshuler LL
Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. Apr 300–304
Lenze EJ see Joo JH
Lépine J-P. Epidemiology of anxiety disorders: prevalence and societal costs. Suppl 14, 4–8
Leppämäki SJ, Partonen TT, Hurme J, Haukka JK, Lönnqvist JK. Randomized trial of the efficacy of bright-light exposure and aerobic exercise on depressive symptoms and serum lipids [CME]. Apr 316–321
Lerner V, Miodownik C, Kaptsan A, Cohen H, Loewenthal U, Kotler M. Vitamin B_6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study. Jan 54–58
Leskelä US see Melartin TK
Lestelä-Mielonen PS see Melartin TK
Leucht S, McGrath J, White P, Kissling W. Carbamazepine augmentation for schizophrenia: how good is the evidence? Mar 218–224
Leung CM, Chung WSD, So EPM. Burning charcoal: an indigenous method of committing suicide in Hong Kong. May 447–450
Leverich GS see McElroy SL
Levine J see Javitt DC
Levinton C see Caro JJ
Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia [letter]. Nov 1045
Lewy AJ see Passmore TA
Liang K-Y see Nestadt G
Libretto SE see Ratnayake T
Lieberman JA, Perkins DO. Introduction. Quetiapine: a 5-year update. Suppl 13, 3–4
Lieberman JA see Lindenmayer J-P
Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. Randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Jan 66–74
Liebowitz MR see Stein DJ
Lin H-N see Shang C-Y
Linden M see Adli M; Hirschfeld RMA
Lindenmayer J-P, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. Oct 931–935
Ling D see Crown WH
Linsley KR see Turkington D
Linszen D see de Haan L
Llorca P-M, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, Faruch M, Macher J-P, Sermet E, Servant D. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. Nov 1020–1027
Loewenthal U see Lerner V
Lomax JW. Review of Graessner S, Gurris N, Pross C (eds): *At the Side of Torture Survivors: Treating a Terrible Assault on Human Dignity.* May 458
Longo LP. Olanzapine for cocaine craving and relapse prevention in 2 patients [letter]. July 595–596
Lönnqvist JK see Leppämäki SJ
Lu BY, Lundgren R, Escalona PR, Roberts BB. Case of ziprasidone-induced mania and the role of 5-HT_{2A} in mood changes induced by atypical antipsychotics [letter]. Dec 1185–1186
Lu R, Hurley AD, Gourley M. Dystonia induced by mirtazapine [letter]. May 452–453
Lu Y see Detke MJ; Goldstein DJ
Lucena MI see García-Pando AC
Lund BC see Perry PJ
Lundgren R see Lu BY
Lusk KM see Zajecka J
MacCabe JH, Marks IM, Murray RM. Behavior therapy attenuates clozapine-induced obsessions and compulsions [letter]. Dec 1179–1180
MacDougall M see Grof P
Macher J-P see Llorca P-M
MacIndoe JH see Perry PJ
Mackert A see Adli M
Madhusoodanan S see Brenner R
Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. Suppl 4, 56–62
Mahmoud RA see Gianfrancesco FD
Maidment KM see Saxena S
Maina G, Vitalucci A, Gandolfo S, Bogetto F. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. Jan 38–43
Maina G see Albert U
Malhotra S, King KH, Welge JA, Brusman-Lovins L, McElroy SL. Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. Sept 802–806
Malhotra S, McElroy SL. Medical management of obesity associated with mental disorders. Suppl 4, 24–32
Mallinckrodt C see Goldstein DJ
Mallinger AG see Fagiolini A
Mallya A, Chawla P, Boyer SK, DeRosear L. Resolution of hyperglycemia on risperidone discontinuation: a case report [letter]. May 453–454
Manber R, Allen JJB, Morris MM. Alternative treatments for depression: empirical support and relevance to women [CME]. July 628–640
Manber R see Ninan PT; Thase ME; Zajecka J
Mancini C see Van Ameringen M
Mann JJ see Tew JD Jr
Mann SC see Caroff SN
Mantle JM see Greist JH
Mantyh PW. Neurobiology of substance P and the NK_1 receptor. Suppl 11, 6–10
Marangell LB, Johnson CR, Kertz B, Zboyan HA, Martinez JM. Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study. May 391–395
Marazziti D see Hollander E
Marchiaro L see Rocca P
Marder SR. Review of Green MF: *Schizophrenia Revealed: From Neurons to Social Interactions.* June 542
Marder SR see Merlo MCG; Tsuang J; Umbricht DS; Wirshing DA
Margolese HC, Annable L, Dion Y. Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. Nov 1040–1044
Margolese HC see Levy E
Markowitz JC see Thase ME
Marks IM see Greist JH; MacCabe JH
Marom S see Bodinger L
Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC. Fluoxetine versus placebo in posttraumatic stress disorder. Mar 199–206
Martín AV see García-Pando AC
Martinez-Arán A see Vieta E
Martinez JM see Marangell LB
Marynchenko MB see Corey-Lisle PK
Masand PS see Kunwar A
Masellis M see Kennedy SH
Massana J see Hirschfeld RMA
Mastalli L see Versiani M

Mathias S, Schaaf LWN, Sonntag A. Eosinophilia associated with olanzapine [letter]. Mar 246–247
Matthews JD, Bottonari KA, Polania LM, Mischoulon D, Dording CM, Irvin R, Fava M. Open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. Dec 1164–1170
Mazlan M see Lee C-T
Mazumdar S see Joo JH
Mazure CM, Frank E. Introduction: women and depression. July 600–609
McCafferty JP see Pollack MH
McCann SM see Kennedy SH
McCoy ML see Meyer PS
McCracken JT, Walkup JT, Koplewicz HS. Childhood and early-onset anxiety: treatment and biomarker studies. Suppl 6, 8–11
McDermut W see Zimmerman M
McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PE, Leverich GS, Altshuler L, Denicoff KD, Nolen WA, Kupka R, Grunze H, Walden J, Post RM. Correlates of overweight and obesity in 644 patients with bipolar disorder. Mar 207–213
McElroy SL see Arnold LM; Freeman MP; Keck PE Jr; Malhotra S
McEnany GW see Zajecka J
McEvoy JP see Lindenmayer J-P
McFall ME see Raskind MA
McGeoch PG see Cohen LJ
McGrath J see Leucht S
McIntyre RS. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. Suppl 3, 15–20
McIntyre RS see Kennedy SH
McKay G see Kennedy SH
McMeniman M see Umbricht DS
McQuade RD see Kane JM
McSorley P see Golden RN
Melartin TK, Rytsälä HJ, Leskelä US, Lestelä-Mielonen PS, Sokero TP, Isometsä ET. Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study. Feb 126–134
Melendrez DC see Krakow BJ
Mellman TA, Bustamante V, David D, Fins AI. Hypnotic medication in the aftermath of trauma [letter]. Dec 1183–1184
Meltzer HY. Introduction: cardiovascular and metabolic risks associated with schizophrenia and antipsychotic drug treatment. Suppl 9, 3–4
Meltzer HY. Review of Remschmidt H (ed): *Schizophrenia in Children and Adolescents.* Mar 252
Meltzer HY, Davidson M, Glassman AH, Vieweg WVR. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. Suppl 9, 25–29
Mendlewicz J see Hirschfeld RMA
Meng LR see Wirshing DA
Merikangas KR see Dierker LC
Merlo MCG, Hofer H, Gekle W, Berger G, Ventura J, Panhuber I, Latour G, Marder SR. Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. Oct 885–891
Metz A see Clayton AH
Metzner JL. Review of Simon RI: *Concise Guide to Psychiatry and Law for Clinicians, 3rd ed.* Nov 1052–1053
Meyer JM. Retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. May 425–433
Meyer PS, Bond GR, Tunis SL, McCoy ML. Comparison between the effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program [CME]. Feb 108–116
Michelson D see Allen AJ
Miner CM, Brown EB, Gonzales JS, Munir R. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. Mar 232–240
Miniati M see Javitt DC
Mintz J see Altshuler LL
Miodownik C see Lerner V
Mischoulon D see Matthews JD
Mitchell JE. Review of Wadden TA, Stunkard J (eds): *Handbook of Obesity Treatment.* Dec 1187–1188
Mitchell PB. Reply to Benazzi F: Clinical features of bipolar depression [letter]. Jan 78
Moffat RR see Pezawas L
Möller H-J. Anxiety associated with comorbid depression. Suppl 14, 22–26
Möller H-J see Ella R; Hirschfeld RMA; Montgomery SA; Rickels K
Montano CB see Clayton AH
Montejo AL. Reply to Haberfellner EM: Role of receptor binding profiles in antidepressant-induced sexual dysfunction [letter]. Feb 168
Montgomery SA, Bech P, Blier P, Möller H-J, Nierenberg AA, Pinder RM, Quitkin FM, Reimitz P-E, Rosenbaum JF, Rush AJ, Stassen HH, Thase ME. Selecting methodologies for the evaluation of differences in time to response between antidepressants [CME]. Aug 694–699
Montgomery SA see Hirschfeld RMA
Morinobu S, Yamashita H, Yamawaki S, Tanaka K, Ohkawa M. Obsessive-compulsive disorder with non–24-hour sleep-wake syndrome [letter]. Sept 838–840
Morris JE. Review of American Psychiatric Press: *American Psychiatric Press Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2000.* Jan 81–82
Morris MM see Manber R
Moutier CY see Feifel D
Mullen JA see Sajatovic M
Müller-Oerlinghausen B see Adli M
Müller-Siecheneder F see Ella R
Mulsant BH see Joo JH; Tew JD Jr
Mundt JC see Greist JH
Munir R see Miner CM
Murray RM see MacCabe JH
Nakano N see Harada K
Nakaya M. Fluvoxamine treatment of a Japanese patient with koro [letter]. Dec 1182–1183
Nand C see Kroll P
Nardi A see Versiani M
Nash JL. Review of Wedding D (ed): *Behavior and Medicine, 3rd ed.* Sept 843
Nasrallah HA. Review of Heinrichs RW: *In Search of Madness: Schizophrenia and Neuroscience.* Sept 845
Nasrallah HA, Tandon R. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. Suppl 13, 12–20
Nasrallah HA see Gianfrancesco FD
Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. Suppl 13, 5–11
Nemeroff CB see Golden RN; Hirschfeld RMA
Nestadt G, Samuels JF, Riddle MA, Bienvenu OJ, Liang K-Y, Grados MA, Cullen B. Obsessive-compulsive disorder: defining the phenotype. Suppl 6, 5–7
Newport DJ, Hostetter A, Arnold A, Stowe ZN. Treatment of postpartum depression: minimizing infant exposures. Suppl 7, 31–44
Nicolson NA see Barge-Schaapveld DQCM
Niehaus DJH see Emsley RA
Nierenberg AA see Montgomery SA
Ninan PT, Rush AJ, Crits-Christoph P, Kornstein SG, Manber R, Thase ME, Trivedi MH, Rothbaum BO, Zajecka J, Borian FE, Keller MB. Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. May 434–441
Ninan PT see Thase ME; Zajecka J
Nolen WA see McElroy SL
Nonacs R, Cohen LS. Depression during pregnancy: diagnosis and treatment options. Suppl 7, 24–30
Normann C, Hummel B, Schärer LO, Hörn M, Grunze H, Walden J. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. Apr 337–344
Oakes R see Liebowitz MR
Oakman J see Van Ameringen M
O'Brien JT see Ballard CG
O'Connor R see Hirsch SR
O'Donovan C, Kusumakar V, Graves GR, Bird DC. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. Apr 322–330
O'Donovan C see Grof P
O'Dowd MA see Gabbay V
Ohayon MM, Lader MH. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. Sept 817–825
Ohkawa M see Morinobu S
Olson N see Kobak KA
Ombao H see Fagiolini A
Onesirosan P see Polsky D
Oosthuizen PP see Emsley RA
Oranje B see Kemner C
Ouslander J see Flacker JM
Overbeek T, Schruers K, Vermetten E, Griez E. Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect. Dec 1106–1112
Ozawa H see Harada K
Özbek H see Ağargün MY
Ozer OA see Ağargün MY
Padberg F see Ella R
Pae C-U see Kim K-S

Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. Sept 796–801
Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. July 559–564
Pallanti S, Rossi NB, Sood E, Hollander E. Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. Nov 1034–1039
Pallanti S see Hollander E
Palmer BW. Review of Lichter DG, Cummings JL (eds): *Frontal-Subcortical Circuits in Psychiatric and Neurological Disorders.* Oct 952
Panhuber I see Merlo MCG
Papatheodorou G see Tauscher-Wisniewski S
Paquet V, Strul J, Servais L, Pelc I, Fossion P. Sleep-related eating disorder induced by olanzapine [letter]. July 597
Park JK see Koh KB
Partonen TT see Leppämäki SJ
Passmore TA, Lewy AJ. Review of the American Psychiatric Association: *Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd ed.* Apr 371
Patel KR see Wirshing DA
Pato CN see **Pato MT**
Pato MT, Pato CN, Pauls DL. Recent findings in the genetics of OCD. Suppl 6, 30–33
Pauls DL see **Pato MT**
Pawlowska M see Brenner R
Peindl KS see Baab SW
Pelc I see Paquet V
Perkins DO. Predictors of noncompliance in patients with schizophrenia [CME]. Dec 1121–1128
Perkins DO see Lieberman JA
Perlmutter IR. Review of Goldstein WN: *A Primer for Beginning Psychotherapy, 2nd ed.* Apr 374
Perry EK see Ballard CG
Perry PJ, Yates WR, Williams RD, Andersen AE, MacIndoe JH, Lund BC, Holman TL. Testosterone therapy in late-life major depression in males. Dec 1096–1101
Perry W see Feifel D
Perugi G, Toni C, Frare F, Travierso MC, Hantouche E, Akiskal HS. Obsessive-compulsive–bipolar comorbidity: a systematic exploration of clinical features and treatment outcome [CME]. Dec 1129–1134
Perugi G see Versiani M
Peskind ER see Raskind MA
Peterson G. EMDR for women who experience traumatic events [letter with reply]. Nov 1047–1048
Petrie EC see Raskind MA
Petti TA. Review of Vance HB, Pumariega AJ (eds): *Clinical Assessment of Child and Adolescent Behavior.* May 457
Pezawas L, Stamenkovic M, Jagsch R, Ackerl S, Putz C, Stelzer B, Moffat RR, Schindler S, Aschauer H, Kasper S. Longitudinal view of triggers and thresholds of suicidal behavior in depression [CME]. Oct 866–873
Philipsen MA see Gleason OC
Piepho RW. Cardiovascular effects of antipsychotics used in bipolar illness. Suppl 4, 20–23
Pierre JM see Wirshing DA
Pies R. Role of micronutrients as possible mood-stabilizing agents [letter with reply]. Aug 742–743
Pinder RM see Montgomery SA
Piontek CM see Baab SW
Pipe B see Van Ameringen M
Pitts CD see Golden RN; Liebowitz MR; Stein DJ
Polania LM see Matthews JD
Pollack MH, Zaninelli R, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK, Goddard A. Reply to Ballas CA: Surprising results in the study of paroxetine for generalized anxiety disorder [letter]. June 536–537
Pollock BG see Joo JH
Polsky D, Onesirosan P, Bauer MS, Glick HA. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans. Feb 156–164
Pope M see Scott J
Poret AW see Crown WH
Post RM see McElroy SL
Posternak MA, Zimmerman M. Anger and aggression in psychiatric outpatients. Aug 665–672
Posternak MA see Zimmerman M
Potter WZ see Spencer T
Power A see Hirsch SR
Poznansky O see Cohen LJ
Pradko JF see Clayton AH
Prakash A see Martenyi F
Prather MR see Schatzberg AF
Pretorius J see Emsley RA
Preuss UW see Ella R
Price BH, Cosgrove GR, Rauch SL, Jenike MA, Cassem EH, Baral I. Reply to Dean CE: Limbic leucotomy in self-mutilation [letter]. Dec 1181
Puca F see Cassano GB
Putz C see Pezawas L
Quercioli L see Pallanti S
Quitkin FM see Montgomery SA
Racy JC. Review of Allen J: *Traumatic Relationships and Serious Mental Disorders.* Sept 846
Rankin M see Fava M
Rao NR. Review of Ayd FJ Jr: *Lexicon of Psychiatry, Neurology and the Neurosciences, 2nd ed.* Feb 171
Rao NSK see Turkington D
Rao R see Yatham LN
Rapaport MH, Endicott J, Clary CM. Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Jan 59–65
Rapkin AJ see Rasgon NL
Rapport DJ see Calabrese JR
Rasgon NL, Altshuler LL, Fairbanks LA, Dunkin JJ, Davtyan C, Elman S, Rapkin AJ. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. Suppl 7, 45–48
Raskin J see Kennedy SH
Raskind MA, Thompson C, Petrie EC, Dobie DJ, Rein RJ, Hoff DJ, McFall ME, Peskind ER. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. July 565–568
Rasmussen SA see Hollander E
Rataemane S see Emsley RA
Ratnayake T, Libretto SE. No complications with risperidone treatment before and throughout pregnancy and during the nursing period [letter]. Jan 76–77
Rauch SL see Price BH
Ravizza L see Hollander E
Regan WM. Review of Stoudemire A, Fogel BS, Greenberg DB (eds): *Psychiatric Care of the Medical Patient, 2nd ed.* Apr 371–372
Reichelt K see Ballard CG
Reimitz P-E see Montgomery SA
Rein RJ see Raskind MA
Reinares M see Vieta E
Remington G see Cohn TA
Reynolds CF III see Joo JH
Rickels K, Möller H-J. Introduction. Anxiety: new treatment perspectives. Suppl 14, 3
Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. Suppl 14, 9–16
Riddle MA see Nestadt G
Rishwain T see Saxena S
Roberts BB see Lu BY
Roberts MC see Emsley RA
Robertson C see Duffy A
Robinson J see Javitt DC
Robinson K see Caro JJ
Rocca P, Marchiaro L, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone. Mar 241–244
Ronis RJ see Feeny NC
Roose SP. Introduction. Treating sexual dysfunction: psychiatry's role in the age of sildenafil. Suppl 5, 3–4
Rosen RM see Saxena S
Rosenbaum JF see Montgomery SA
Rossi NB see Pallanti S
Rothbaum BO see Ninan PT
Rounsaville BJ see Sinha R
Roy A. Characteristics of opiate dependent patients who attempt suicide. May 403–407
Roychowdhury SM see Lee C-T
Ruiz P. Review of Yilmaz AT, Weiss MG, Riecher-Rössler A (eds): *Cultural Psychiatry: Euro-International Perspectives.* Feb 170
Runnerstam M see Sjögren MJC
Rush AJ see Charney DS; Crown WH; Montgomery SA; Ninan PT; Schatzberg AF; Thase ME; Zajecka J
Russell JM see Crown WH
Rynn M see Rickels K
Rytsälä HJ see Melartin TK
Sachs G see Zajecka JM
Sachs GS see Calabrese JR; Suppes T
Sagduyu K. Association of mild traumatic brain injury with bipolar disorder [letter]. July 594
Saha AR see Kane JM
Saito T see Harada K
Saiz J see Hirschfeld RMA
Saiz PA see Bobes J
Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. Dec 1156–1163

Salomon RM. Review of Dilts SL Jr: *Models of the Mind: A Framework for Biopsychosocial Psychiatry*. Jan 80
Samuels JF see Nestadt G
Sanberg PR see Shytle RD
Sánchez AS see García-Pando AC
Santana EM see Krakow BJ
Santarelli L, Gobbi G, Blier P, Hen R. Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK_1). Suppl 11, 11–17
Sarles RM. Review of Greenhill LL (ed): *Learning Disabilities: Implications for Psychiatric Treatment*. June 540–541
Sasaki N see Harada K
Sasson Y see Hollander E
Saunders CS see Wirshing DA
Savino M see Versiani M
Saxena S, Maidment KM, Vapnik T, Golden G, Rishwain T, Rosen RM, Tarlow G, Bystritsky A. Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment [CME]. Jan 21–27
Saxena S see Hollander E
Saylor KE, Buermeyer CM, Spencer TJ, Barkley RA. Adaptive changes related to medication treatment of ADHD: listening to parents of children in clinical trials of a novel nonstimulant medication. Suppl 12, 23–28
Scapicchio PL see Cassano GB
Scarrow G see Yatham LN
Schaaf LWN see Mathias S
Schärer LO see Normann C
Schatzberg AF, Prather MR, Keller MB, Rush AJ, Laird LK, Wright CW. Clinical use of nefazodone in major depression: a 6-year perspective. Suppl 1, 18–31
Schatzberg AF see Thase ME
Schindler S see Pezawas L
Schooler NR see Umbricht DS
Schrader R see Krakow BJ
Schruers K see Overbeek T
Schulz SC see Adityanjee
Schwab JJ. Review of Gunderson JG: *Borderline Personality Disorder: A Clinical Guide*. Dec 1187
Schwartz MA. Nicotine-induced angiogenesis [letter with reply]. Oct 949–950
Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors [CME]. May 384–390
Seabolt JL see Dunner DL
Seidman SN. Exploring the relationship between depression and erectile dysfunction in aging men. Suppl 5, 5–12
Sermet E see Llorca P-M
Servais L see Paquet V
Servant D see Llorca P-M
Shang C-Y, Soong W-T, Lin H-N. Hypokalemia with venlafaxine [letter]. Nov 1049–1050
Shear MK see Harkness KL
Sheehan DV. Management of panic disorder. Suppl 14, 17–21
Sheitman B see Lindenmayer J-P
Shelton MD see Calabrese JR
Shiloh R see Bodinger L
Shin YC see Kim SW
Shon SP see Suppes T
Shytle RD, Silver AA, Sanberg PR. Reply to Schwartz MA: Nicotine-induced angiogenesis [letter]. Oct 949–950
Sigmund JA. Sildenafil advertising and the realities of sildenafil treatment [letter]. Dec 1183
Silander HC see Sjögren MJC
Silberman RA see Harkness KL
Silipo G see Javitt DC
Silver AA see Shytle RD
Silverman JJ. Review of Gunderson JG, Gabbard GO (eds): *Psychotherapy for Personality Disorders (Review of Psychiatry series, vol. 19)*. May 457
Simpson JSA see Kaplan BJ
Sinha R, Rounsaville BJ. Sex differences in depressed substance abusers [CME]. July 616–627
Sisley BN see Krakow BJ
Sjögren MJC, Hellström PTO, Jonsson MAG, Runnerstam M, Silander HC, Ben-Menachem E. Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: a pilot study. Nov 972–980
Skolnick P. Beyond monoamine-based therapies: clues to new approaches. Suppl 2, 19–23
Slaughter JR. Review of White CA: *Cognitive Behaviour Therapy for Chronic Medical Problems: A Guide to Assessment and Treatment in Practice*. Apr 372–373
Smith SL see Charney DS; DeVane CL
Smith KW see Freeman MP
So EPM see Leung CM
Soares CN, Joffe H, Cohen LS, Almeida OP. Efficacy of 17β-estradiol on depression: is estrogen deficiency really necessary? [letter with reply] May 451
Sokero TP see Melartin TK
Sol O see Llorca P-M
Sommerville KW see Zajecka JM
Sonntag A see Mathias S
Sood E see Pallanti S
Soong W-T see Shang C-Y
Spadone C see Llorca P-M
Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. Dec 1140–1147
Spencer TJ, Biederman J, Wilens TE, Faraone SV. Novel treatments for attention-deficit/hyperactivity disorder in children. Suppl 12, 16–22
Spencer TJ, Biederman J, Wilens TE, Faraone SV. Overview and neurobiology of attention-deficit/hyperactivity disorder. Suppl 12, 3–9
Spencer TJ see Saylor KE
Stack JA see Joo JH
Stahl SM. Antipsychotic polypharmacy: squandering precious resources? [Brainstorms] Feb 93–94
Stahl SM. Awakening to the psychopharmacology of sleep and arousal: novel neurotransmitters and wake-promoting drugs [Brainstorms]. June 467–468
Stahl SM. Can psychopharmacologic treatments that relieve symptoms also prevent disease progression? [Brainstorms] Nov 961–962
Stahl SM. Does depression hurt? [Brainstorms] Apr 273–274
Stahl SM. Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder [Brainstorms]. Sept 756–757
Stahl SM. Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents [Brainstorms]. Oct 854–855
Stahl SM. Metabolic syndrome: psychopharmacologists should weigh the evidence for weighing the patient [Brainstorms]. Dec 1094–1095
Stahl SM. Mirror, mirror on the wall, which enantiomer is fairest of them all? [Brainstorms] Aug 656–657
Stahl SM. Psychopharmacology of energy and fatigue [Brainstorms]. Jan 7–8
Stahl SM. Psychopharmacology of painful physical symptoms in depression [Brainstorms]. May 382–383
Stahl SM. Psychopharmacology of wakefulness: pathways and neurotransmitters [Brainstorms]. July 551–552
Stahl SM. Selective actions on sleep or anxiety by exploiting GABA-A/benzodiazepine receptor subtypes [Brainstorms]. Mar 179–180
Stamenkovic M see Pezawas L
Stamm T see Adli M
Stampfer R see Ella R
Stapf DA see Kupfer DJ
Stassen HH see Montgomery SA
Steele VM see Borovicka MC
Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. Feb 152–155
Stein DJ, Westenberg HGM, Liebowitz MR. Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. Suppl 6, 12–19
Stein DJ see Emsley RA
Stein K see Burt VK
Stein MB see Liebowitz MR; Stein DJ
Stelzer B see Pezawas L
Stoner SC, Dubisar BM, Khan R, Farrar CD. Severe hypertriglyceridemia associated with olanzapine [letter]. Oct 948–949
Stowe ZN see Newport DJ
Strain JJ. Review of Sadock BJ, Sadock VA (eds): *Kaplan & Sadock's Pocket Handbook of Clinical Psychiatry, 3rd ed.* Oct 952–953
Strakowski SM see Fleck DE
Strul J see Paquet V
Such P see Hirschfeld RMA
Sullivan JR see Calabrese JR
Sullivan KA see Caroff SN
Sundblad C see Eriksson E
Suppes T, Dennehy EB. Evidence-based long-term treatment of bipolar II disorder. Suppl 10, 29–33
Suppes T, Dennehy EB, Swann AC, Bowden CL, Calabrese JR, Hirschfeld RMA, Keck PE Jr, Sachs GS, Crismon ML, Toprac MG, Shon SP, for the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. Report of the Texas Consensus

Conference Panel on Medication Treatment of Bipolar Disorder 2000. Apr 288–299
Suppes T see Calabrese JR; McElroy SL
Sussman N see Dunner DL
Swann AC see Suppes T; Zajecka JM
Swartz HA see Fagiolini A
Sweitzer DE see Sajatovic M
Tanaka K see Morinobu S
Tancer M see Liebowitz MR
Tandon R see Nasrallah HA
Tariot PN, Ismail MS. Use of quetiapine in elderly patients. Suppl 13, 21–26
Tarlow G see Saxena S
Tauscher J see Tauscher-Wisniewski S
Tauscher-Wisniewski S, Kapur S, Tauscher J, Jones C, Daskalakis ZJ, Papatheodorou G, Epstein I, Christensen BK, Zipursky RB. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. Nov 992–997
Taylor LvH see Kobak KA
Terao T. Palinopsia and paroxetine withdrawal [letter]. Apr 368
Termine A see Vessicchio JC
Tew JD Jr, Mulsant BH, Haskett RF, Dolata D, Hixson L, Mann JJ. Randomized comparison of high-charge right unilateral electroconvulsive therapy and bilateral electroconvulsive therapy in older depressed patients who failed to respond to 5 to 8 moderate-charge right unilateral treatments. Dec 1102–1105
Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder see Suppes T
Tham JC, Dickson RA. Clozapine-induced fevers and 1-year clozapine discontinuation rate. Oct 880–884
Thase ME, Rush AJ, Manber R, Kornstein SG, Klein DN, Markowitz JC, Ninan PT, Friedman ES, Dunner DL, Schatzberg AF, Borian FE, Trivedi MH, Keller MB. Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. June 493–500
Thase ME. Studying new antidepressants: if there were a light at the end of the tunnel, could we see it? [commentary]. Suppl 2, 24–28
Thase ME. What role do atypical antipsychotic drugs have in treatment-resistant depression? Feb 95–103
Thase ME see Montgomery SA; Ninan PT; Zajecka J
Thompson C see Raskind MA
Thompson T. Review of Došen A, Day K (eds): *Treating Mental Illness and Behavior Disorders in Children and Adults With Mental Retardation.* Mar 252–253
Tombul T see Ağargün MY
Toni C see Perugi G
Toprac MG see Suppes T
Torrent C see Vieta E
Torta R see Hirschfeld RMA
Trabucchi M see Cassano GB
Tran PV see Lee C-T
Travierso MC see Perugi G
Trieschmann ME see Fernandez HH
Trivedi MH see Ninan PT; Thase ME; Zajecka J
Tsai S-J see Huang S-C
Tsai S-YM, Kuo C-J, Chen C-C, Lee H-C. Risk factors for completed suicide in bipolar disorder. June 469–476
Tsuang J, Marder SR, Han A, Hsieh W. Olanzapine treatment for patients with schizophrenia and cocaine abuse [letter]. Dec 1180–1181
Tunis SL see Meyer PS
Turkington D, Grant JBF, Ferrier IN, Rao NSK, Linsley KR, Young AH. Randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Sept 778–781
Turner J see Emsley RA
Umbricht DS, Wirshing WC, Wirshing DA, McMeniman M, Schooler NR, Marder SR, Kane JM. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. May 420–424
Vaillant GE. Review of Tseng W-S: *Handbook of Cultural Psychiatry.* July 598–599
Valevski A see Bodinger L
Van Ameringen M, Mancini C, Pipe B, Campbell M, Oakman J. Topiramate treatment for SSRI-induced weight gain in anxiety disorders. Nov 981–984
van Engeland H see Kemner C
van Kammen DP see Berlant J
van Megen H see Denys D
van Meter S see Weisler RH
Vapnik T see Saxena S
Vasilakis-Scaramozza C see Kornegay CJ
Ventura J see Merlo MCG
Verbaten MN see Kemner C
Vermetten E see Overbeek T
Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. Jan 31–37
Versiani M see Hirschfeld RMA
Vessicchio JC, Termine A, George TP. Smoking cessation and panic attacks: a report of 2 cases [letter]. July 594–595
Vieira A see Appolinario JC
Vieta E, Martinez-Arán A, Goikolea JM, Torrent C, Colom F, Benabarre A, Reinares M. Randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. June 508–512
Vieweg WVR. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs. Suppl 9, 18–24
Vieweg WVR see Meltzer HY
Virk S see Kunwar A
Visanuyothin T see Lee C-T
Vitalucci A see Maina G
Volavka J see Lindenmayer J-P
Wahid ZU. Review of Gerrity E, Keane TM, Tuma F (eds): *The Mental Health Consequences of Torture (Plenum Series on Stress and Coping).* Aug 747
Wahlbeck K see Ahokas A
Walden J see McElroy SL; Normann C
Walker DJ see Lee C-T
Walkup JT see McCracken JT
Wan DDC see Lam RW
Wang A see Lee C-T
Wang H see Lee C-T
Wang PW see Ketter TA
Wang R-h see Gianfrancesco FD
Ward A see Caro JJ
Warner TD see Krakow BJ
Watras-Gans S see Cohen LJ
Weber EM see Joo JH
Weinstein DD. Review of Schuckit MA: *Drug and Alcohol Abuse: A Clinical Guide to Diagnosis and Treatment, 5th ed.* May 459
Weisler R see Zajecka JM
Weisler RH, van Meter S. Rapid onset of antidepressant activity with venlafaxine [letter with reply]. June 534–535
Weissman MM, Jensen P. What research suggests for depressed women with children [CME]. July 641–647
Weizman A see Bodinger L
Welge JA see Arnold LM; Malhotra S
Wenzel KW see Greist JH
Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. Suppl 12, 50–55
Westenberg H see Denys D
Westenberg HGM see Stein DJ
White JC see Borovicka MC
White P see Leucht S
Whiteside JE see Goldberg JF
Wilens TE see Spencer TJ
Williams RD see Perry PJ
Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. Effects of novel antipsychotics on glucose and lipid levels. Oct 856–865
Wirshing DA, Boyd JA, Pierre JM, Saunders CS, Wirshing WC, Azizian K, Patel KR, Ashcraft JC, Darmandjian H, Feusner J. Delusions associated with quetiapine-related weight redistribution [letter]. Mar 247–248
Wirshing DA, Pierre JM, Wirshing WC. Sleep apnea associated with antipsychotic-induced obesity [letter]. Apr 369–370
Wirshing DA see Umbricht DS
Wirshing WC see Umbricht DS; Wirshing DA
Wisner KL see Baab SW
Wittchen H-U, Kessler RC, Beesdo K, Krause P, Höfler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. Suppl 8, 24–34
Wittchen H-U see Kessler RC
Wong MMC see Lee C-T
Wozniak P see Zajecka JM
Wright CW see Charney DS; Schatzberg AF
Wright R see Freeman MP
Wynn JD. Review of Slavney PR, Hurko O (eds): *The Primary Care Physician's Guide to Common Psychiatric and Neurologic Problems: Advice on Evaluation and Treatment From Johns Hopkins.* Aug 746–747
Yamada S see Kawashima T
Yamashita H see Morinobu S
Yamawaki S see Morinobu S
Yates WR see Gleason OC; Perry PJ
Yatham LN. Introduction: innovations in the management of bipolar disorders. Suppl 3, 3–4
Yatham LN. Role of novel antipsychotics in bipolar disorders. Suppl 3, 10–14

Yatham LN, Kusumakar V, Calabrese JR, Rao R, Scarrow G, Kroeker G. Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. Apr 275–283
Yonkers KA, Brawman-Mintzer O. Pharmacologic treatment of depression: is gender a critical factor? [CME] July 610–615
Young AH see Turkington D
Zajecka J, Dunner DL, Gelenberg AJ, Hirschfeld RMA, Kornstein SG, Ninan PT, Rush AJ, Thase ME, Trivedi MH, Arnow BA, Borian FE, Manber R, Keller MB. Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. Aug 709–716
Zajecka J, McEnany GW, Lusk KM. Antidepressant dosing and switching guidelines: focus on nefazodone. Suppl 1, 42–47
Zajecka J see Dunner DL; Ninan PT
Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. Comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. Dec 1148–1155
Zanarini MC see Frankenburg FR
Zaninelli R see Kim SW; Pollack MH
Zboyan HA see Marangell LB
Zemishlany Z see Bodinger L
Zhang H see Martenyi F
Zimbroff DL see Kane JM
Zimmerman M, Breen RB, Posternak MA. Open-label study of citalopram in the treatment of pathological gambling. Jan 44–48
Zimmerman M, Chelminski I, McDermut W. Major depressive disorder and axis I diagnostic comorbidity [CME]. Mar 187–193
Zimmerman M see Posternak MA
Zipursky RB see Tauscher-Wisniewski S
Zohar J see Hollander E
Zwanzger P see Ella R

Move beyond print to the JCP "Cyber-Index"

The year-end Index provides convenient and traditional assistance to search this volume of the Journal on your library bookshelf. But, the most efficient way to search multiple volumes is only a keystroke away.

To find articles on complex subjects or to find articles from past issues, just visit WWW.PSYCHIATRIST.COM. Here you can browse issues of JCP back to 1996 and capitalize on full-text search capability to find exactly what you're looking for.

We're here to meet your needs—the JCP printed index is your quick guide to the best of this year and the "Cyber-Index" is your best guide to quickly collate knowledge that spans the years.

Physicians Postgraduate Press, Inc.
Our focus is lifelong learning for physicians

Find it all @ www.PSYCHIATRIST.com